



**PUSHPAGIRI**  
COLLEGE OF DENTAL SCIENCES  
NAAC ACCREDITED



# CODE OF ETHICS IN RESEARCH

Pushpagiri College of Dental Sciences  
Tiruvalla.

# **CODE OF ETHICS IN RESEARCH**

## **INTRODUCTION**

Pushpagiri College of Dental Sciences is committed to promoting and maintaining high standards of integrity and accountability in the conduct of academic research and is keen to embed and endorse a culture of honesty and transparency in all its institutional activities. In undertaking this commitment, the College emphasizes that academic freedom is a core value to be safeguarded and sustained. We are dedicated to ensuring a free academic environment to conduct research, to teach, to speak, publish, subject to the norms and standards of scholarly inquiry. Research and developmental activities create and disseminate new knowledge, promote innovation and motivate better learning and teaching and this has been incorporated in our courses.

Research begins from the first year of admission in graduation and is a part of the post-graduate curriculum. Faculty are also encouraged to participate and/or conduct research individually. As the research work is being conducted at all levels in this institute, the code of ethics in research is an inseparable and integral part to set forth general principles of ethical conduct to guide scholars toward the highest ideals of scholarly research. Grants from various international and national agencies like ICMR, DBT, DST, SERB, NANOMISSION, KSCSTE, Bill & Melinda Gates Foundation, etc. whose funding enables us to provide essential research resources to its scholarly community. The institute abides by the highest standards of integrity in the conduct of academic research and/or support to academic research activities.

## **PRINCIPLES AND ETHICAL VALUES IN RESEARCH**

Academic integrity requires that academic research follows elevated professional standards, including:

Appropriate research design and frameworks

Adheres to high levels of research ethics

Abides by the requirements set out by professional and regulatory research guidance and research ethics frameworks issued in appropriate areas.

Academic integrity is defined in terms of the commitment to the values of honesty, trust, fairness, respect, responsibility, legality, and dissemination.

Honesty: An academic community should advance the quest for truth, knowledge, scholarship, and understanding by requiring intellectual and personal honesty in learning, teaching, and research.

Trust: An academic community should foster a climate of mutual trust to encourage the free exchange of ideas and enable all to reach their highest potential.

Fairness: An academic community should seek to ensure fairness in institutional standards, practices, and procedures as well as fairness in interactions between members of the community.

Respect: An academic community should promote respect among students, staff, and faculty: respect for self, for others, for scholarship and research, for the educational process and intellectual heritage.

Responsibility: An academic community should uphold high standards of conduct in learning, teaching, and research by requiring shared responsibility for promoting academic integrity among all members of the community.

Legality: An academic community should observe valid legal norms related to the conduct and publication of research particularly with copyright, the intellectual property rights of third parties, the terms and conditions regulating access to research resources, and the laws of the land.

Communication: An academic community should seek to make the results of its research as widely and as freely available as possible.

## **INSTITUTIONAL RESPONSIBILITIES**

The principal, the vice principals, the head of departments, and faculty members are responsible for promoting and endorsing a transparent academic environment conducive to the application of high professional and ethical criteria of good practice for academic research. Research guides are expected to create and sustain a climate of mutual co-operation that facilitates the open exchange of ideas and the development of academic

research skills. They are also expected to ensure the provision of appropriate supervision and direction for researchers, following the nature of the individual academic discipline and associated mode of research. The institute is committed to providing appropriate direction to the research along with supervision for researchers. Guides are expected to adhere to the norms during the assessment of research progress, and procedures to resolve problems during research activity.

### **RESEARCH DATA MANAGEMENT**

All original research data on which publications have been or will be based, in some cases samples or materials derived from the ongoing research, should be well-documented and safely archived to keep data from being manipulated and to make data accessible for future reference for a period of time adequate for a given discipline.

### **RESEARCH PROCEDURES**

All research studies should be preceded by the risk and consequences analysis to foresee how research results may affect society and the environment. When applying for research funding, the researchers should formulate realistic goals and make every effort to accomplish them. Special care should be taken in the case of research studies carried out on human subjects. Human dignity and an individual's autonomy must be respected at all costs. All research subjects, living organisms, the environment, or cultural objects, should be handled with respect and care. The health, safety, or welfare of a community or collaborators should not be compromised. Researchers should be aware of the need for balanced management of research funding. In special, justified cases, the confidentiality of data or research findings should be respected by the researchers.

### **PUBLICATION PRACTICE AND AUTHORSHIP**

The institute encourages the publication and dissemination of results of high-quality research. It also expects that researchers will engage in the process of publishing and dissemination of their work responsibly and with an awareness of the consequences of any such dissemination in the wider media. Results should be published in a form appropriate to the academic discipline. The institute requires that all individuals listed as authors accept responsibility for the contents of the publication and can identify their contribution to it. Authors should have

participated sufficiently in the research to take public responsibility for the content. Authorship must be based solely on substantial intellectual contribution to the research. This includes significant contribution in initiating the scientific idea, formulating conceptions, designing research, significant share in data acquisition, in the analysis and interpretations of data, and in drafting the article or revising it critically for intellectual content. Acquisition of funding, provision of technical assistance or materials, the collection of data, general supervision of the research group, by themselves, do not justify authorship. All authors are fully responsible for the content of the publication unless it is specified, they are responsible only for a specific part of the study within their specialty. When listing authors and their affiliations, it is appropriate to mention what was the nature of their contribution to the research. The sequence of authors should be consistent with the existing customs in a given scientific discipline and agreed by all, ideally at the start of the project. Intellectual contributions of others that have influenced the reported research should be appropriately acknowledged. Financial or other types of research support should be properly mentioned and acknowledged. Publication of the same (or substantial parts of the same) work in different journals is acceptable only with the consent of the editors of the journals and where proper reference is made to the first publication. The institute encourages the faculty and students to follow the recommendations of ICJME (International Committee of Medical Journal Editors).

## **THE ETHICS COMMITTEE**

Tasks of the ethics Committee:

To provide advice and guidance to the academic community on all matters of academic research ethics

To advise the academic council on compliance with the 'Code of Ethics in Academic Research' of the various academic activities at the college.

To provide guidance and academic support to scholars on ethical issues in respect of teaching, research, and other academic activities.

To advise the academic council of any policies that may be required concerning accepting funds from particular sponsors of research.

To act as an investigative/consultative body for any disputed matter concerning research ethics and conduct

### **PEER REVIEW AND ASSESSMENT**

Reviewers should not agree to peer review any research, scientific achievements, or research concepts of other scientists when the research falls outside their areas of expertise. Reviewers involved in the review process concerning research projects, publications, scientific achievements, applications for faculty positions in scientific institutions, and other forms of recognition, should withdraw from involvement in the review process if there is any conflict of interests between them and evaluated individuals. Reviewers should provide accurate, objective, substantiated, and justifiable assessments. Reviewers should maintain confidentiality until the manuscript is published. Reviewers and editors shall not make any use of the data or ideas presented in submitted manuscripts without the author's permission.


### **TRAINING**

The academic departments should ensure that all researchers undertake appropriate training in research design, methodology, regulatory and ethics approvals and consents, equipment use, confidentiality, data management, record-keeping, data protection and publication, the appropriate use of licensed research resources, and respect for the intellectual property rights of third parties.

### **AVOIDING CONFLICT OF INTEREST**

There are non-professional relationships between the evaluator and the evaluated, be that individual or institution. There is a connection between a member of the fund granting authority and a person or research unit to which these funds are granted.

**Dr. Aby Mathew T. MDS**  
Principal  
Pushpagiri College of Dental Sciences



# **INSTITUTIONAL ETHICS COMMITTEE**

**Pushpagiri Institute of Medical Sciences,**

**Pushpagiri Research Centre,**

**Thiruvalla, Kerala – 689101**

**Ph: 0469 2775518**

**Email: [pushpagiriirb@pushpagiri.in](mailto:pushpagiriirb@pushpagiri.in)**

## **STANDARD OPERATING PROCEDURES**

**INSTITUTIONAL ETHICS COMMITTEE**

**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**

**PUSHPAGIRI RESEARCH CENTRE,**

**THIRUVALLA, KERALA-689101, INDIA**

**STANDARD OPERATING PROCEDURES**

	<b>Name</b>	<b>Designation</b>	<b>Signature</b>	<b>Date</b>
Prepared by	Dr. Liya Roslin	Basic Medical Scientist		
	Dr. Philip Mathew	Clinician		
	Dr. Nibu Varghese	Scientific Member		
	Dr. Prasanth Rathinam	Supporting Staff		
Reviewed By	Dr. Nebu George Thomas	Member Secretary		
Approved By	Dr. Harikumar B Nair	Chairman		
Authorized By	Dr. T P Thankappan	Principal		



## **LIST OF ETHICS COMMITTEE MEMBERS**

<b>Sl No</b>	<b>Name</b>	<b>Gender</b>	<b>Qualification</b>	<b>Designation in the EC</b>	<b>Affiliation</b>
1	Dr. Harikumar Bhaskaran Nair	M	BAMS (AYURVEDA PHYSICIAN)	Chairman	Not Affiliated
2	Dr. Nebu George Thomas	M	MDS (Periodontics)	Member Secretary	Affiliated
3	Dr. Vikram Gowda	M	MD (Physiology)	Basic Medical Scientist	Affiliated
4	Dr. T P Thankappan	M	MD (Dermatology, Venereology & Leprosy)	Clinician	Affiliated
5	Dr. Philip Mathew	M	MD - Community Medicine	Clinician	Affiliated
6	Adv. Minu Mathews	F	LLM	Legal Expert	Not Affiliated
7	Fr. Sabin Mathew	M	Bachelor in Theology	Social Scientist	Not Affiliated
8	Lijo George	M	B. COM	Lay Person	Not Affiliated
9	Dr. Tressia Alias Princy Paulose	F	DOCTORATE IN CHEMISTRY	Scientific Member	Not Affiliated
10	T M CHARRY	M	DOCTORATE IN BIOCHEMISTRY	Scientific Member	Not Affiliated
11	Dr. G SULOCHANA	F	MD - PATHOLOGY & MICROBIOLOGY	Basic Medical Scientist	Not Affiliated
12	Dr. NIBU VARGHESE	M	DOCTORATE IN PLANT BIOTECHNOLOGY	Scientific Member	Affiliated
13	STEPHEN JAMES	M	MTech CS-IT	Member	Not Affiliated
14	Dr. Athulya G Asokan	F	MD - General Medicine	Clinician	Affiliated

### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla

Version : 1.0 Dated:20<sup>th</sup> Nov 2019

**LIST OF ETHICS COMMITTEE MEMBERS**

15	Dr. LIYA ROSLIN JOSEPH	F	MD - Pharmacology	Basic Medical Scientist	Affiliated
----	---------------------------	---	-------------------	----------------------------	------------

## INDEX

Sl.No	Table of Contents	Page Number
<b>Chapter 1</b>	<b>Preparation and implementation of Standard Operating Procedures (SOPs)</b>	
1.0	Purpose	
2.0	Scope	
3.0	Procedures	
4.0	Responsibilities of Chairperson	
5.0	IEC Member	
6.0	Secretariat of IEC	
	<b>Annexures</b>	
	1.Flow chart of SOP implementation	
	2.SOP issue log	
<b>Chapter 2</b>	<b>Authority And Procedure To Form Ethics Committee</b>	
1.0	Purpose	
2.0	Scope	
3.0	Authority to constitute EC	
4.0	Criteria for selection of members	
5.0	Roles and responsibilities of IEC	
	<b>Annexures:</b>	

	1. Memorandum of Understanding with Chairman	
	2. Format of the invitation letter from HOI to EC members	
	3.Format for the Consent/acceptance letter for EC members	
	4.Format for the appointment letter for EC members	
	5.Format for the confidentiality Agreement	
	6.Format for the CV	
	7. Format for the conflict of interest Agreement	
<b>Chapter 3</b>	<b>Constitution Of Institutional Ethics Committee</b>	
1.0	Purpose	
2.0	Ethical Basics for Constitution of EC	
3.0	Terms of Reference of IEC	
4.0	Responsibilities of IEC members	
5.0	Composition of IEC	
6.0	Roles and Responsibilities of EC members	
6.1	Chairperson	
6.2	Member Secretary	
6.3	Basic Medical Scientist	
6.4	Clinician	
6.5	Legal Expert	

**Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla

Version : 1.0 Dated:20<sup>th</sup> Nov 2019

6.6	Social Scientist/Philosopher/Ethicist/Theologian	
6.7	Lay person(s)	
7.0	IEC Secretariat	
8.0	The IEC Administrative Staff Roles and Responsibilities	
9.0	Duties of the Administrative Staff	
	Terms of Membership	
10.0	Procedure for resignation, removal and replacement of IEC members	
11.0	Meeting Procedures	
12.0	Quorum Requirement	
13.0	Policy to prevent conflict of interest	
14.0	Policy regarding training and updating IEC members	
15.0	Independent Consultants	
	<b>Annexures</b>	
	1.Format for Confidentiality Agreement for Independent Consultants	
<b>Chapter 4</b>	<b>Management of Submission of Applications</b>	
1.0	Purpose	
2.0	Types of research review by Ethics committee And Responsibility	

5.0	Minimum required documents for submission of research project for approval.	
	Meeting Frequency of IEC	
	Submission requirement	
6.0	Receive submission packages	
	<b>Annexures</b>	
	1.Submission Checklist	
	2.Template for submission letter	
	3.Dispatch Return Log	
<b>Chapter 5</b>	<b>Agenda, Preparation, Review &amp; Meeting Procedures and Recording of Minutes</b>	
1.0	Purpose	
2.0	Scope	
3.0	Responsibility	
4.0	Before full board IEC meeting	
4.1	Preparation of the meeting	
4.2	Detailed procedure	
4.3	Element of Review	
4.4	Expedited Review	
4.5	Full Committee Review	
4.6	Review of protocol amendment	

4.7	Periodic Review	
4.8	Annual Review	
4.9	Review of protocol deviation/violation	
4.10	Review of studies involves vulnerable population	
4.11	Research involving pregnant women and fetuses	
4.12	Research involving children	
4.13	Decision Making	
5.0	After the IEC meeting	
5.1	Preparing the minutes and the decision letters	
5.2	Approval of the minutes and the decisions	
5.3	Filing of the minutes of the meeting	
5.4	Communicating the decision with the investigator	
	<b>Annexures</b>	
	1.Template for approval letter	
	2.ICD review checklist	
	3.Protocol review checklist	
	4.CTA review checklist	
	5.IB review checklist	
	6.Agenda	
	7.Application for annual review	

<b>Chapter 6</b>	<b>Site Monitoring</b>	
1.0	Purpose	
2.0	Scope	
3.0	Responsibility	
4.0	Procedure	
5.0	Before the visit	
6.0	During the visit	
7.0	After the visit	
	<b>Annexures</b>	
	1.Monitoring check list	
	2.Monitoring report template	
<b>Chapter 7</b>	<b>Protection of subject rights safety and well being</b>	
1.0	Purpose	
2.0	Scope	
3.0	Responsibility	
	<b>Annexures</b>	
	1.Subject Complaint Form	
	2.Register Template	
<b>Chapter 8</b>	<b>Administrative Support for EC</b>	
1.0	Purpose	



2.0	Scope	
3.0	Administrative Support	
4.0	Financial Operations	
5.0	Honorarium to EC members	
	<b>Annexures</b>	
	1.EC fee	
	2.Payment receipt voucher	
<b>Chapter 9</b>	<b>Communication with stake holders</b>	
1.0	Purpose	
2.0	Scope	
3.0	Communication with regulatory	
4.0	Communication with the investigator	
5.0	Communication with the HOI	
	<b>Annexures</b>	
	1.Reminder letter to investigator	
<b>Chapter 10</b>	<b>Review of serious adverse event and other safety reports</b>	
1.0	Purpose	
2.0	Scope	
3.0	Responsibility	

4.0	Definition of Serious Adverse Event (SAE)	
5.0	Procedure for reporting SAE	
6.0	Compensation in case of injury or death during clinical trial	
7.0	Procedure for payment of financial compensation	
7.1	<ul style="list-style-type: none"> <li>The case of SAE of death shall be examined as given below</li> </ul>	
7.2	<ul style="list-style-type: none"> <li>Cases of SAE, other than deaths, shall be examined as given below.</li> </ul>	
8.0	Review of SUSAR/CIOMS	
	<b>Annexures</b>	
	1.Appendix XI	
	2.Due analysis report template	
	3.Compensation Formula	
<b>Chapter 11</b>	<b>Self-Assessment Process</b>	
1.0	Purpose	
2.0	Scope	
3.0	Responsibility	
4.0	Assessment of EC members	
	<b>Annexures</b>	
	1.Audit Checklist	

	2.Assessment Form for EC Members	
<b>Chapter 12</b>	<b>Record Keeping and Archival</b>	
1.0	Purpose	
2.0	Scope	
3.0	Detailed procedure	
4.0	Documents that should be filed and archived	
5.0	Retrieval Procedure	
6.0	Final disposal of documents	
	<b>Annexures</b>	
	1.Document Tracking Register	
	2.Document Request Form	
<b>Chapter 13</b>	<b>Preparing for Ethics Committee Audit/Inspection</b>	
1.0	Purpose	
2.0	Scope	
3.0	Responsibility	
4.0	Detailed instructions	
4.1	Receipt of notification of an audit/inspection	
4.2	Preparing for the audit	
4.3	On the day/s of visit	
4.4	Correction of deficiencies observed at	

	audit/inspection	
4.5	Recording the Audit/Inspection Visit	
	<b>Annexure</b>	
	1.Checklist	

**INSTITUTIONAL ETHICS COMMITTEE**  
**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**  
**PUSHPAGIRI RESEARCH CENTRE,**  
**THIRUVALLA, Kerala-689101, India**

**Ph: 0469 2775518**

**STANDARD OPERATING PROCEDURES**

**CHAPTER -1**

**PREPARATION AND IMPLEMENTATION OF STANDARD  
OPERATING PROCEDURE**

## **CHAPTER -1**

### **PREPARATION AND IMPLEMENTATION OF STANDARD OPERATING PROCEDURES**

#### **1.0 Purpose**

This Standard Operating Procedures (SOP) defines the process for writing, reviewing, distributing, and amending SOPs within the Institutional Ethics Committee (IEC). The SOPs will provide clear, unambiguous instructions to conduct activities of the IEC in accordance with the ICMR guidelines Schedule YII and ICH (International Conference on Harmonization) Good Clinical Practice (GCP).

#### **2.0 Scope**

This SOP Chapter covers the procedures of writing, reviewing, distributing, and amending SOPs within the IEC.

#### **Procedure and Responsibilities**

The SOP shall be prepared according to the applicable regulatory requirements and it shall be approved by Chairperson of the Ethics Committee. SOP shall be revised time to time to meet the new regulatory requirements. The need of a revision of SOP shall be discussed in the IEC meeting and Chairperson shall appoint SOP writing team to revise the SOP.

The proposal for amendment shall be submitted to the Member Secretary. The proposal for amendment shall be presented to the regular members at a scheduled committee meeting. Only regular members shall vote to accept or reject the proposed amendment. A proposed amendment will be approved by a vote of three-fourths of the members present in a quorum at a scheduled committee meeting, rounded to the next whole number.

It is the responsibility of Chairperson of the IEC to appoint the SOP writing Team to formulate the SOPs. SOP writing team will consist of Member Secretary of IEC, administrative staff and one or two other IEC members

## *Chapter 1 : Preparation and implementation of standard operating procedures*

SOP writing team will prepare the draft SOP. The draft SOPs will be reviewed and approved by the IEC members. SOP writing team will be responsible to amend the SOPs as and when required.

SOPs will be reviewed by the members of IEC. The Chairpersons of IEC will approve the SOPs. The SOPs will then be approved by Head of Institution, as these are SOPs for Institutional Ethics Committee for Research Review.

Approved SOPs will be implemented from the effective date. The Member Secretary will discuss the approved SOPs with the administrative staff and instruct them to implement the SOP accordingly. Training on New SOP will be conducted for all members.


The EC Members will be trained on SOPs annually and whenever there is revision in the SOP. The training records will be maintained by EC

Old SOPs should be retained and clearly marked –superseded and archived in a file by the secretariat. The process of evolution of previous SOPs of the IEC will be documented in a defined format.

### **ANNEXURES**

1. Flow chart of SOP implementation
2. SOP Issue Log

1. Flow chart of SOP implementation





**2 SOP Issue Log**

No	Name of the Recipient	Designation	SOP details	No. of Copies	Date Issued	Signature of the recipient

**INSTITUTIONAL ETHICS COMMITTEE**  
**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**  
**PUSHPAGIRI RESEARCH CENTRE,**

**Thiruvalla, Kerala-689101, India**

**Ph: 0469 2775518**

**STANDARD OPERATING PROCEDURES**

**Chapter 2**

**AUTHORITY AND PROCEDURE TO FORM ETHICS**  
**COMMITTEE**

## **CHAPTER 2**

### **AUTHORITY AND PROCEDURE TO FORM ETHICS COMMITTEE**

#### **1.0 Purpose**

This SOP Chapter shall mention about the authority under which EC is constituted and its procedures for forming Ethics Committee.

#### **2.0 Scope**

The SOP Chapter applies to the formation of the EC.

#### **3.0 Authority to constitute IEC**

The Head of the institution or person who plays equivalent position from the Institution has the authority for constitution of Ethics Committee. The head of institution will select a Member Secretary from the institution to form Ethics Committee. The Head of Institution and Member Secretary will identify a Chairperson who is not affiliated to the institution by any means. The head of institution will have Memorandum of Understanding with Chairperson. All other EC members are appointed by the Head of the Institution in consultation with chairperson / Member Secretary.

#### **Criteria for selection of members:**

- Members are selected in their personal capacities, based on their interest, ethical and/or scientific knowledge and expertise, experience in the domain field and profile.
- The members representing medical scientist and clinicians should have post graduate qualification & adequate experience in their respective fields
- Conflict of interest will be avoided while making appointments, but where unavoidable, there will be transparency with regard to such interests.
- Directors, Head of Institution, Superintendents, Administrative officers who are responsible for business development will not serve as members of IEC.
- New members will be identified according to the requirement

All EC members will receive invitation letter from Head of Institution and all EC Members

#### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

## Chapter 2 : Authority And Procedure To Form Ethics Committee

will sign acceptance to be part of the study and Confidentiality agreement. The office of Member secretary will act as the administrative office of EC. An updated CV will be collected from the invited members and Medical registration certificates will be collected for the members who are medically qualified.

The Ethics committee will maintain its independence from political, institutional, professional and market influences in the composition, procedures, and decision-making process. The head of Institution would ensure that its Members are competent enough to review a proposal submitted to them and at the same time they are free to express their thoughts and expressions in an unbiased manner.

EC would function in accordance with the Declaration of Helsinki, Good Clinical Practice, Schedule Y and all the applicable national and international guidelines for biomedical research.

The details of the Head of Institution, EC Chairperson and Member Secretary are given below:

Name of Head of the Institution:	<b>Dr. T P Thankappan</b>
Mailing address :	Head of the Institute, Pushpagiri Institute of Medical Sciences and Research Centre, Thiruvalla - 689101
Contact No:	0469 2775518
Fax:	04692600020
Email:	tpthankappan@gmail.com
Name of the Chairman of EC:	<b>Dr. HARIKUMAR BHASKARAN NAIR</b>
Mailing address :	N.S.S. Ayurveda Hospital, Vallankulam, Eraviperoor-689542 Kerala
Contact No:	+91 9447114492

Fax:	
Email:	doctorhari@gmail.com
Name of the Member Secretary:	Dr. Nebu George Thomas
Mailing address :	Pushpagiri Institute of Medical Science Pushpagiri Research Centre Mother and child block, Thiruvalla, Pathanamthitta, Kerala - 689101
Contact No:	9447044726
Fax:	04692600020
Email:	nebugt@gmail.com

## ANNEXURES

- a) Memorandum of Understanding with EC Chairperson
- b) Format of invitation letter from Head of the institute to EC Members
- c) Format for the acceptance letter/ Consent to be a member of IEC for IEC members
- d) Name and Address of the member
- e) Confidentiality agreement for members
- f) Format for the Curriculum Vitae
- g) Template for Conflict of Interest for members
- h) Appointment letter

**a) Memorandum of Understanding with EC Chairperson**

**MEMORANDUM OF UNDERSTANDING (MOU)**

This MOU made and entered into on -- <Date> (effective date) between Institutional Ethics Committee - <Name and address>(Here after represented as Institution) represented by its Head of the Institute <Name of the HOI>And <Name of the Chairman> having address < enter the address> (here after represented as EC Chairperson).

Institution and EC Chairman hereinafter are individually referred to as -the Partyll and are jointly referred to as -the Partiesll.

**Where as**

- The Institution is involved in providing healthcare services
- The Ethics committee is the committee functioning in the hospital to review and oversee the biomedical research conducting in the hospital
- Institution appoints EC Chairperson to head the ethics committee and EC Chairman accepts the invitation
- In view of the above, the parties have entered into this MOU on the terms and conditions mentioned herein below:

**ROLES AND RESPONSIBILITES OF THE PARTIES**

The roles and responsibilities of the parties are as mention below. The parties agree that they shall abide by the roles and responsibilities described and defined hereafter.

**EC Chairman**

1. Conduct EC Meetings and be accountable for independent and efficient functioning of the committee
2. Ensure active participation of all members (particularly non-affiliated, non-medical/ non-technical) in all discussions and deliberations
3. Ratify minutes of the previous meetings

## *Chapter 2 : Authority And Procedure To Form Ethics Committee*

4. In case of anticipated absence of Chairman at a planned meeting, the Chairman should nominate a committee member as Acting Chairman or the members present may elect an Acting Chairman on the day of the meeting. The acting Chairman should be a non-affiliated person and will have all the powers of the Chairman for that meeting.
5. Seek Conflicts of Interest declaration from members and ensure quorum and fair decision making.
6. Handle complaints against researchers, EC members, conflict of interest issues and requests for use of EC data, etc.
7. To protect the dignity, rights, safety and well-being of the potential research participants.
8. To ensure that universal ethical values and international scientific standards are expressed in terms of local community values and customs.
9. To assist in the development and education of a research community responsive to local health care requirements.
10. For this purpose, EC shall look into the aspects of informed consent process, risk benefit ratio, distribution of burden and benefit and provisions for appropriate compensations wherever required.
11. Provide documents pertaining affiliation, qualification and training.
12. Assessment of EC Members

### **INSTITUTION**

1. Institution to provide an office for the EC.
2. The institution should provide space, infrastructure and staff to the EC for maintaining a full-time secretariat, safe archival of records and conduct of meeting.
3. Institution should allocate reasonable funds for smooth functioning of the EC
4. Receive and review the reports provided by the Chairperson as per standard Operating Procedure.
5. Approve Standard Operating Procedures
6. Provide administrative requirements for the EC
7. Provide adequate honorarium for the participants of the meeting.

#### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

## 2. DURATION

The MOU shall be valid with effect from the effective date and shall continue to be in force for a period of Three years

## 3. TERMINATION

Either party may terminate this MOU by giving one month written notice to the other party

## 4. CONFIDENTIALITY

At all-time during the term of this MOU and thereafter each party shall hold in strictest confidence and shall not disclose, use, lecture upon or publish any of the other party's proprietary information, except as such disclosure, use or publication may be required in connection with such party's performance of its obligations under this MOU. The term -proprietary informationll shall mean trade secrets, confidential knowledge, data or any other proprietary information of the party.

## 5. ARBITRATION

In the event of any dispute arising out of or in connection with this MOU, the parties wish to seek an amicable settlement as per the laws of India and Kerala.

Executed by their duly authorized representatives on the date(s) shown below.

Accepted and Signed by Hospital and EC Chairman

### For INSTITUTION

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Date: \_\_\_\_\_

### For EC CHAIRMAN

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Date: \_\_\_\_\_



**b) Format of invitation letter from Head of the institute to ECMembers**

**Invitation Letter**

Date:

From,

Name and Address of the director

To,

Name and Address of the member

Sub: Invitation to join as a Member of Institutional Ethics Committee

Dear Sir / Madam,

On behalf of Pushpagiri Institute of Medical Sciences, Pushpagiri Research Centre, Thiruvalla, Kerala - 689101, I request you to accept my invitation to be a member of Institutional Ethics committee. Kindly send your written acceptance in the enclosed format and provide the necessary information requested.

Yours sincerely,

Signature:

Name of the director

c) **Format for the acceptance letter/ Consent to be a member of IEC for IEC members**

**Acceptance Letter/ Consent to be a member of IEC**

From

Name and Address of the member

To

Name and Address of director

Sub: Acceptance/Consent to be a member of IEC Regarding.

Ref: Your letter dated:

Dear Sir,

In response to your letter stated above, I accept the invitation to become a member of Institutional Ethics committee. I shall regularly participate in the Institutional Ethics committee meeting to review and give my unbiased opinion regarding the ethical issues.

I shall be willing to publicize my full name, profession and affiliation.

I shall make available to the public on request, all reimbursement for work and expenses, if any, related to Institutional Ethics committee

I shall not keep any literature or study related document with me after the discussion and final review.

I shall maintain all the research project related information confidential and shall not reveal the same to any one other than project related personnel.

I herewith enclose my CV.

Thanking You,

Yours sincerely,

Signature -----

Name of Member. ----- Date:

Address

Telephone No: (Off)\_\_\_\_\_ (Res)\_\_\_\_\_ Email:

**d) Format of the appointment letter from HOI to EC Members**

**Appointment Letter**

Date:

From,

Name and Address of the HOI

To,

Name and Address of the member

Sub: Appointment letter as a Member of Institutional Ethics Committee

Dear Sir / Madam,

On behalf of Pushpagiri Institute of Medical Sciences, Pushpagiri Research Centre, Thiruvalla, Kerala - 689101, I hereby appoint you as a member of Institutional Ethics Committee. You shall be designated the role of

.....

<<Terms of reference>>.

Your roles and responsibilities in the EC will be as follows:

<<Roles and responsibilities>>

Yours sincerely,

Signature:

Name:

**e) Format for Confidentiality Agreement by the EC Members**

**Confidentiality agreement**

To,

Institutional Ethics Committee

Pushpagiri Institute of Medical Sciences,

Pushpagiri Research Centre, Thiruvalla, Kerala – 689101

I understand that I being a member of Institutional Ethics Committee Pushpagiri Institute of Medical Sciences, Pushpagiri Research Centre, Thiruvalla, Kerala - 689101, I may acquire or may have already acquired knowledge of or access to, information concerning with the various research studies from companies.

I understand that this confidential information is the exclusive property of the study sponsor / Pushpagiri Institute of Medical Sciences, Pushpagiri Research Centre, Thiruvalla, Kerala - 689101.

I understand to keep this information strictly confidential. I will not disclose to any third party the information and contents of the confidential documents without prior written consent from Institutional Ethics Committee.

Signature : \_\_\_\_\_

Name : \_\_\_\_\_

Date : \_\_\_\_\_

**f) Format for the Curriculum Vitae**

**Curriculum Vitae**

Name	:	
Educational Qualifications:		
Qualification	Institution	Year of passing
Medical Reg. No. (If applicable)	:	
Residential Address	:	
Current Organization	:	
Nature of Current organization (Gov/Pvt/Aided/Autonomus)	:	
Official Address (With designation)	:	
Currently Affiliated/Not Affiliated with Pushpagiri Institute of Medical Sciences, Pushpagiri Research Centre, Thiruvalla	:	
Current Profession	:	
Professional Experience:		
Designation/Role	Institute	Period
List of Publications (if any)	:	
<b><u>Personal Details</u></b>		
Gender	:	
Date of Birth	:	
Nationality	:	
Phone No.	:	
Email Id	:	

**g) Template for Conflict of Interest for members**

**Agreement on Conflict of Interest**

In accordance of the policy of the IEC, I shall not participate in the review, comment or approval of any activity in which I have a conflict of interest, except to provide information as requested by the IEC. The Undersigned will immediately disclose to the Chairperson of the IEC any actual or potential conflict of interest that I may have in relation to any particular proposal submitted for review by the committee, and to abstain from any participation in discussions or recommendations in respect of such proposals.

Whenever I have a conflict of interest, I shall immediately inform the committee not to count me toward a quorum for consensus or voting.

I, ..... have read and I accept the aforementioned terms and conditions as explained in this Agreement.

-----

Signature Date

**INSTITUTIONAL ETHICS COMMITTEE**  
**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**  
**PUSHPAGIRI RESEARCH CENTRE,**

Thiruvalla, Kerala-689101, India

Ph: **0469 2775518**

**STANDARD OPERATING PROCEDURES**

**Chapter 3**

**CONSTITUTION OF INSTITUTIONAL ETHICS**  
**COMMITTEE**

## **CHAPTER 3**

### **CONSTITUTION OF INSTITUTIONAL ETHICS COMMITTEE**

#### **1.0 Purpose**

The IEC shall be established to formalize and specify Institution's commitment to the promotion of high scientific and ethical standards in patient care, professional education, clinical research, and community interests.

#### **Ethical Basics for Constitution of EC**

- The committee will consist of members who collectively have the qualifications & experience to review & evaluate the scientific, medical & ethical aspects of a proposed research project.
- In evaluating protocols and ethical issues, the IEC is aware of the diversity of laws, culture and practices governing research and medical practices in various countries around the world and especially in India.
- It attempts to inform itself where possible of the requirements & conditions of the various localities where proposed research is being considered.
- The IEC is guided in its reflection, advice & decision by the ethical principles expressed in WMA declaration of Helsinki- Ethical principles for medical research involving Human subjects.
- Adopted by the 18<sup>th</sup> WMA General Assembly, Helsinki, Finland, June 1964, and amended by the :
  - 29<sup>th</sup> WMA General Assembly, Tokyo, Japan, October 1975
  - 35<sup>th</sup> WMA General Assembly, Venice, Italy, October 1983
  - 41<sup>st</sup> WMA General Assembly, Hong Kong, September 1989
  - 48<sup>th</sup> WMA General Assembly, Somerset West, Republic of South Africa, October 1996
  - 52<sup>nd</sup> WMA General Assembly, Edinburgh, Scotland, October 2000
  - 53<sup>rd</sup> WMA General Assembly, Washington 2002 (Note of clarification on paragraph 29 added)
  - 55<sup>th</sup> WMA General Assembly, Tokyo 2004 (Note of clarification on paragraph 30 added)

#### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019



59<sup>th</sup> WMA General Assembly, Seoul, October 2008

- It makes further reference to the International Ethical Guidelines for e.g.: The Nuremberg Code(1945), Belmont Report (1979), The council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines for Biomedical Research involving Human Subjects (Geneva 2002), and the European convention on Human rights & Biomedicine (1997).
- The IEC will ensure that the research protocols submitted by Clinical investigators are sound , scientifically designed, have statistical validity and are conducted according to the parameters of ICH-GCP, Indian GCP, Declaration of Helsinki, ICMR & Schedule Y as local regulatory requirements.
- The IEC is established and functions in accordance with the relevant national law and regulations in force from time to time.

### **Terms of Reference of IEC**

The terms of reference for the IEC are as follows:

- Ensure the highest scientific and ethical standards of research
- Review and approve proposals for clinical, basic or translational research projects (Intra and Extra mural) for scientific and ethical content
- Improve ethical standards and issue guidelines
- To function as a forum to advise the administration in case of any ethical issues that may arise from patients, families or public
- To maintain leadership as a national standard of reference in all fields
- To issue and periodically, update and revise SOP s and guidelines for effective functioning of IEC as and when necessary
- Continuing education in clinical research bioethics and ethical aspects of clinical practice by seminars, workshops and interactive discussions for all categories of staff members including nursing and paramedical staff
- To initiate and commission research studies on ethical aspects of practice.

### **Responsibilities of IEC**

- To protect and safeguard the dignity, rights, safety and well-being of all actual or potential research participants.

#### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

- To ensure that the research projects that are carried out are sound in design, have statistical validity and are conducted according to the ICMR, Schedule Y and ICH/GCP guidelines
- To consider the principle of justice, that the benefits and burdens of research be distributed fairly among all groups and classes in society taking into account age, gender, economic status, culture and ethics consideration.
- To provide advice to the researchers on all aspects of the welfare and safety of research participants after ensuring the scientific soundness of the proposed research.
- To ensure the research are conducted under the supervision of trained medical / bio medical persons with the required expertise
- To ensure that research will include, solely, patients or participant who have given voluntary and informed consent
- It may be ensured that no research project shall be / can be started unless Ethics Clearance / Approval is obtained.
- It will review the proposals before start of the studies as well as monitor the research throughout the study until and after completion by examining the annual reports and final reports. The committee will also examine whether all regulatory requirements and laws are complied with or not.

### **5.0 Composition of IEC:**

EC should be Multi-disciplinary and multi- sectorial. There should be adequate representation of age and gender. Preferably 50% Member will be non-affiliated or from the outside the organization. The number of Members in an EC should be between 7 and 15. The EC should have a balance between medical and non-medical members/ Technical and non-technical members depending up on the needs of the institution.

- The Ethics Committee shall have a minimum of seven members from medical, non-medical, scientific and non-scientific areas with at least,
  - i. one lay person;
  - ii. one woman member;
  - iii. one legal expert;

### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated: 20<sup>th</sup> Nov 2019

### *Chapter 3 : Constitution Of Institutional Ethics Committee*

- iv. one independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian.
- One member of the Ethics Committee who is not affiliated with the institute or organization shall be the Chairperson, and shall be appointed by such institute or organisation.
- One member who is affiliated with the institute or organization shall be appointed as Member Secretary of the Ethics Committee by such Institute or organization.
- The committee shall include at least one member whose primary area of interest or specialisation is non-scientific and at least one member who is independent of the institution.
- The members of the Ethics Committee shall follow the provisions of these rules, Good Clinical Practices Guidelines and other regulatory requirements to safeguard the rights, safety and well-being of trial subjects.
- Every member of the Ethics Committee shall be required to undergo such training and development programmes as may be specified by the Central Licencing Authority from time to time: Provided that any member, who has not successfully completed such training and developmental programmes, shall be disqualified to hold the post of member of the Ethics Committee and shall cease to be a member of such committee.
- The members representing medical scientists and clinicians shall possess at least post graduate qualification in their respective area of specialisation, adequate experience in the respective fields and requisite knowledge and clarity about their role and responsibility as committee members.
- As far as possible, based on the requirement of research area such as Human Immunodeficiency Virus (HIV) or genetic disorder, specific patient group may also be represented in the Ethics Committee.
- No member of an Ethics Committee, having a conflict of interest, shall be involved in the oversight of the clinical trial or bioavailability or bioequivalence study protocol being reviewed by it and all members shall sign a declaration to the effect that there is no conflict of interest.

- While considering an application which involves a conflict of interest of any member of the Ethics Committee, such member may voluntarily withdraw from the Ethics Committee review meeting, by expressing the same in writing, to the Chairperson.
- The details in respect of the conflict of interest of the member shall be duly recorded in the minutes of the meetings of the Ethics Committee.

## **Roles and Responsibilities of EC Members**

### **Chairperson**

Chairperson will be Non affiliated. A well respected person from any background with prior experience of having served/ serving in an EC.

### **Responsibilities**

- Conduct EC Meetings and be accountable for independent and efficient functioning of the committee
- Ensure active participation of all members (particularly non-affiliated, non-medical/ non-technical) in all discussions and deliberations
- Ratify minutes of the previous meetings
- In case of anticipated absence of Chairperson at a planned meeting, the Chairperson should nominate a committee member as Acting Chairperson or the members present may elect an Acting Chairperson on the day of the meeting. The acting Chairperson should be a non-affiliated person and will have all the powers of the Chairperson for that meeting.
- Seek COI declaration from members and ensure quorum and fair decision making.
- Handle complaints against researchers, EC members, conflict of interest issues and requests for use of EC data, etc

### **Member Secretary**

Member Secretary will be affiliated with the institution. Should be a staff member of the institution, Should have knowledge and experience in clinical research and ethics, be motivated and have good communication skills, Should be able to devote adequate time to this activity which should be protected by the institution

**Responsibilities**

- Organize an effective and efficient procedure for receiving, preparing, circulating and maintaining each proposal for review
- Schedule EC meetings, prepare the agenda and minutes
- Organize EC documentation, communication and archiving
- Ensure training of EC secretariat and EC members
- Ensure SOPs are updated as and when required
- Ensure adherence of EC functioning to the SOPs
- Prepare for and respond to audits and inspections
- Ensure completeness of documentation at the time of receipt and timely inclusion in agenda for EC review.
- Assess the need for expedited review or full review
- Assess the need to obtain prior scientific review, invite independent consultant, patient or community representatives.
- Ensure quorum during the meeting and record discussions and decisions.

**Basic Medical Scientist**

Medical scientist can be Affiliated/ non-affiliated . He/she should be Non-medical or medical person with qualifications in basic medical sciences, In case of EC reviewing clinical trials with drugs, the basic medical scientist should preferably be a pharmacologist. The representative of Medical scientist category should have postgraduate qualification & adequate experience in their respective fields.

**Responsibilities**

- Scientific and ethical review with special emphasis on the intervention, benefit-risk analysis, research design, methodology and statistics, continuing review process, SAE, protocol deviation, progress and completion report
- For clinical trials, pharmacologist to review the drug safety and pharmacodynamics

**Clinician**

He should be affiliated/ non-affiliated Qualifications - Should be individual/s with recognized Post Graduate medical qualification, expertise and training

**Responsibilities**

- Scientific review of protocols including review of the intervention, benefit-risk analysis, research design, methodology, sample size, site of study and statistics
- Ongoing review of the protocol (SAE, protocol deviation or violation, progress and completion report)
- Review medical care, facility and appropriateness of the principal investigator, provision for medical care, management and compensation.
- Thorough review of protocol, investigators brochure (if applicable) and all other protocol details and submitted documents

**Legal expert/s**

He should be Affiliated/ non-affiliated with the institution .Should have a basic degree in Law from a recognized university, with experience.

**Responsibilities**

- Ethical review of the proposal, ICD along with translations, MoU, Clinical Trial Agreement (CTA), regulatory approval, insurance document, other site approvals, researcher's undertaking, protocol specific other permissions, compliance with guidelines etc.
- Interpret and inform EC members about new regulations if any

**Social scientist/ philosopher/ ethicist/theologian**

Non-affiliated persons with social/ behavioural science/ philosophy/ religious qualification and training and/or expertise and be sensitive to local cultural and moral values. Can be from an NGO involved in health-related activities

**Responsibilities**

- Ethical review of the proposal, ICD along with the translations.
- Assess impact on community involvement, socio-cultural context, religious or philosophical context, if any

- Serve as a patient/participant/ societal / community representative and bring in ethical and societal concerns.

**Lay person(s)**

Non-affiliated Literate person from the public or community , Has not pursued a medical science/ health related career in the last 5 years , May be a representative of the community from which the participants are to be drawn , Is aware of the local language, cultural and moral values of the community , Person involved in social and community welfare activities are desirable

**Responsibilities**

- Ethical review of the proposal, ICD along with translation(s).
- Evaluate benefits and risks from the participant’s perspective and opine whether benefits justify the risks.
- Serve as a patient/participant/ community representative and bring in ethical and societal concerns.
- Assess on societal aspects if any

**IEC Secretariat**

The Secretariat is composed of the Member Secretary and the administrative supporting staff. The supporting staff consists of staff members of Asirvatham Hospital appointed by the Head of Institution.

The secretariat shall have the following functions:

- Organization of an effective and efficient tracking procedure for each proposal received.
- Preparation, maintenance and distribution of study files.
- Organization of regular IEC meetings. .
- Preparation of the agenda and the minutes of the meetings,
- Maintenance of the IEC records and archives.
- Communication with IEC members and Principal Investigators.
- Arrangement of training for personnel and IEC members.
- Provision of the necessary administrative support for IEC related activities to the Member Secretary, IEC.

**Standard operating procedure**

- Receipt of IEC processing fees for projects and the issue of official receipts for the same.

### **The IEC Administrative Staff Roles and Responsibilities**

The administrative staff will help the IEC Chairperson and Member Secretary in executing functions of the IEC. Additional staff may be appointed and duties assigned as and when deemed necessary by the IEC. The administrative staff will be appointed by the Head of Institution by formal interview or direct appointment.

- Organizing an effective and efficient tracking procedure for each proposal received.
- Preparing, maintaining and distributing study files.
- Organizing IEC meetings regularly
- Preparing the agenda and minutes of the meetings
- Maintaining IEC records and archives.
- Communicating with IEC members and PIs.
- Arranging training for personnel and IEC members
- Providing necessary administrative support for IEC related activities to the Member Secretary, IEC.
- Receiving IEC processing fees and issuing official receipts for the same.
- Corresponding with the IEC members, external experts and investigators.
- Making the pre and post arrangements of IEC meetings.
- Preparing the agenda and minutes of the IEC meetings.
- Answering queries of the investigators.
- Filing study related documents.
- Archiving and maintaining the study files.
- Preparation for accreditation, Registration and audits
- Training for investigators, key study personnel, IEC members, and IEC staff.
- Participate in the development and subsequent implementation of SOPs
- Developing an effective and efficient tracking procedure



### Terms of Membership

- The members are drawn from different specialties to give a multi-sectorial, multidimensional structure. A one page current Curriculum Vitae (CV) will be collected from each member and filed in the administrative file.
- The duration of appointment is initially for a period of 3 years
- At the end of 3 years, the committee will be reconstituted, by the discretion of the Head of the institution
- A member can be replaced in the event of death or long-term assignments outside the country or for any misconduct deemed unfit for a member.
- A member will also be removed if they fail to attend atleast three consecutive meetings unless proper reason for the absence is communicated in advance in writing.
- If a member is found acting code of conduct (or) objectives of the committee, he or she can be removed by 2/3<sup>rd</sup> majority of the members subject to issue of notice seeking objection which is to be submitted within two weeks on receipt of the notice. On the expiry of two weeks the committees to consider the representation received from the members and decide the action of removal. If the committee is satisfied with the reply, it can drop the action of removal. If not satisfied, the committee can remove the member by passing a resolution to this effective in a meeting to be convened 21 days after sending notice to all the members.
- A member can tender resignation with proper reasons to do so, in writing to the Head of Institution and Chairperson of Ethics committee.
- All members should maintain absolute confidentiality of all discussions during the meeting. A confidentiality agreement will be signed from each member and filed with EC before joining in the EC

### Meeting Procedures

- The IEC meetings are held trimonthly. Additional meetings may be held as and When considered necessary.
- The Investigator's team should submit the documents 2 weeks prior to the scheduled meeting to IEC. The applicant is required to submit 5 copies of his / her application letter and copies of the documents.
- The notice of each meeting with the agenda is sent out to the members at least one

#### Standard operating procedure

*Chapter 3 : Constitution Of Institutional Ethics Committee*  
week before the meeting.

- A quorum is required for all meetings. The project can be approved unanimously or by non-unanimously. When it is approved unanimously, an approval letter will be prepared and signed by chairman and member secretary. If some members are objecting the study to be approved, chairman will take the voting from the members to see the majority and if majority is there the project will be approved. In that case the voting status also will be mentioned in the approval letter.
- Member secretary will prepare the minutes of the meetings and circulated to all the members. The final minutes of the meeting will be kept in the minutes of the meetings file signed by the Chairman.

### **Quorum Requirement**

- In a meeting, atleast five members should be present to meet the quorum requirements; to review and make a written decision on any application. None of the members present in the meeting must not have conflict of interest.

### *Chapter 3 : Constitution Of Institutional Ethics Committee*

- Each Quorum (with a minimum of 5 members) should have following members
  - a. Clinician
  - b. Basic Medical Scientist (Preferably Pharmacologist)
  - c. Legal Expert
  - d. Social Scientist / Representative of Non-Governmental Voluntary Agency
  - e. Lay Person from Community
- If a quorum is not present during the course of the meeting, EC Meeting can be adjourned by Chairperson.
- Chairperson can nominate a member secretary during the absence of Member Secretary
- In the absence of Chairperson EC Members can select a Member as a Chairperson for that meeting. But the selected Member should not be affiliated to the institution
- All types of changes and situations should be documented in the Minutes of meeting of the EC

#### **Policy to prevent conflict of interest**

- The ultimate interest of Ethics committee is to prevent conflict of interest.
- It has been recognized that the potential for conflict of interest will always exist, but Chairperson is capable to manage the conflict issues so that the ultimate outcome is the protection of human subjects.
- There should be no conflict of interest.
- The members shall voluntarily withdraw from the Ethics Committee meeting while making a decision on an application which evokes a conflict of interest which may be indicated in writing to the Chairman prior to the review
- Chairperson can also ask the members to declare Conflict of interest during the meeting.
- All members shall sign a declaration on conflict of interest.
- All the declaration regarding conflict of interest should be mentioned in the minutes of Meeting.

#### **Policy regarding Training and Updating IEC members**

- All relevant new guidelines to be brought to the attention of the members.

#### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

### *Chapter 3 : Constitution Of Institutional Ethics Committee*

- Members should be encouraged to attend national and international training programs in research ethics for maintaining quality in ethical review and to be aware of the latest developments in this area.
- All EC members must be conversant with ICMR Guidelines for Research involving Human Subjects, Schedule Y of Drugs and Cosmetics Act and ICH-GCP guidelines.
- All the members will be given training on the above-mentioned guidelines and rules yearly basis. A training record would be maintained for the same.
- Every new member will get trained on all of the above-mentioned guidelines and rules at the time of appointment.
- When a new rule/ guideline / sop revision has happened, all the members would be trained and training record would be maintained for the same.
- The Trainer will be invited from outside or from within the IEC and background and profile of the trainer will be documented
- All the training records which includes Agenda, Attendance, Pretest, Post test, Feedback forms training materials and Training logs will be maintained in the Training File

#### **Independent Consultants**

The IEC may call upon, or establish a standing list of, independent consultants who may provide special expertise to the IEC on proposed research protocols, when the Chairperson / Member secretary or the IEC members determine that a study will involve procedures or information that is not within the area of expertise of the IEC members. These consultants may be specialists in ethical or legal aspects, specific diseases or methodologies (e.g. genetic disorders, stem cell research etc.), or they may be representatives of communities, patients, or special interest groups. These consultants or subject experts cannot vote for a decision.

#### **ANNEXURES**

1. Confidentiality Agreement Form for Independent Consultant

#### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

**Confidentiality Agreement**

I, ..... understand that I am allowed to attend the ethics committee meeting as a subject expert/independent consultant. In the course of the meeting of the IEC, some confidential information may be disclosed or discussed. Upon signing this form, I agree to take reasonable measures to keep the information as confidential.

\_\_\_\_\_  
Signature of the Guest or Observer

\_\_\_\_\_  
Date

**INSTITUTIONAL ETHICS COMMITTEE PUSHPAGIRI**

**INSTITUTE OF MEDICAL SCIENCES,**

**PUSHPAGIRI RESEARCH CENTRE,**

Thiruvalla, Kerala-689101, India

Ph: **0469 2775518**

**STANDARD OPERATING PROCEDURES**

**Chapter 4**

**MANAGEMENT OF SUBMISSION OF APPLICATIONS**

## **CHAPTER 4**

### **MANAGEMENT OF SUBMISSION OF APPLICATIONS**

#### **1.0 Purpose**

This SOP is designed to describe and act as a guideline for the IEC Secretariat to manage research study submissions.

#### **2.0 Types of research review by Ethics committee And Responsibility**

The Ethics Committee will review Clinical Trials (Phase II, Phase III, Phase IV) epidemiological studies, retrospective studies, herbal studies and studies for devices.

It is the responsibility of the IEC secretariat to receive record and distribute the study documents for IEC review.

#### **3.0 Minimum required documents for submission of research project for approval**

An application for review of the ethics of proposed biomedical research should be submitted by a qualified applicant responsible for the ethical and scientific conduct of the research. Principal Investigator can submit the documents for IEC for review and approval. All relevant documents should be enclosed with a covering letter and Submission Checklist.

#### **Meeting Frequency of IEC**

- The committee will hold regular meetings trimonthly. When there are no research proposals to review, the meeting may be hold less frequently, but no less than once every three months
- The Member Secretary will schedule the meeting either at the time of the previous scheduled meeting or within 2 weeks after new project submission and consult the Chairperson / IEC members to schedule and reconfirm the meeting date.

#### **Submission Requirements**

- The application should be submitted two weeks before the EC meeting date.
- 5 number of the hard copies of the proposal; along with the application and documents in prescribed format

- Prescribed fee as per the Fee Structure should be remitted along with the application
- The following list of documents to be submitted by Applicant for review by EC
  - a. Trial Protocol: Submit the latest protocol along with all the amendments mentioning the version no. (s) and date(s).
  - b. Patient Information Sheet and Informed Consent Form: Submit the latest Patient Information Sheet(s) and Informed Consent Form (s) in English and all the applicable vernacular languages mentioning the version no. (s) and date(s).
  - c. AV consent form
  - d. Investigator's Brochure: Submit the latest Investigator's brochure mentioning the version no. (s) and date(s).
  - e. Proposed methods for patient accrual including advertisement if applicable (s) etc. proposed to be used for the purpose.
  - f. Principal Investigator's signed and dated current CV along with medical registration certificate.
  - g. Insurance Policy / Compensation for participation and for serious adverse events occurring during the study participation.
  - h. Investigator's Agreement with the Sponsor.
  - i. Investigator's undertaking, as per Schedule Y – Appendix VII format.
  - j. The Regulatory approval / submission status from sponsor for the conduct of study.
  - k. Description of site facilities using in the study including available emergency facilities
  - l. A description of the process to be used to obtain the informed consent.

### **Receive submission packages**

For the initial review of study, investigators should submit all study related documents to the IEC, two weeks before the next scheduled meeting. The procedure for the receipt of documents are as follows :

- EC Secretariat will review the documents submitted.
- If any missing documents are there EC will inform the applicant to submit the required documents



## *Chapter 4 : Management Of Submission Of Applications*

- If the application is intact, the member secretary will give acknowledgement in the submission letter by signing and stamping for investigator use.
- Each Hard copy of the documents will be distributed to each of the members to their address and soft copy will be mailed to their official email id before 14 days before the EC meeting
- One copy will be stored at EC office which will be labeled as Master copy and this copy will be archived at EC office
- Agenda will be prepared by EC office and distributed to all EC members 7 days prior to the meeting.

### **ANNEXURES**

1. Submission Checklist
2. Template for Submission letter
3. Dispatch Return Log

**1. Submission Checklist**

S.No	Contents	Applicant Section		Ethics Committee Section		Comments
		Yes	No	Yes	No	
1.	Name of the applicant with designation	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
2.	Name of the Institute/ Hospital / Field area where research will be conducted	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
3.	Approval of the Head of the Department / Institution if applicable	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
4.	Protocol of the proposed research	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
5.	Ethical issues in the study and plans to address these issues.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
6.	Proposal should be submitted with all relevant enclosures like proformae, case report forms, questionnaires, follow - up cards, etc.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
7.	Informed consent process, including patient information sheet and informed consent form in local language(s).	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
8.	For any drug / device trial, all relevant pre-clinical animal data and clinical trial data from other centers within the country / countries, if available.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
9.	Current Curriculum vitae of all the investigators	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
10.	Regulatory Approval/ Submission status	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
11.	Source of funding and financial requirements for the project	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
12.	Insurance and Indemnity arrangements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
13.	Description of site facilities using in the study including available emergency facilities	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

*Chapter 4 : Management Of Submission Of Applications*

S.No	Contents	Applicant Section		Ethics Committee Section		Comments
		Yes	No	Yes	No	
14.	Investigator Undertaking	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
15.	Agreement to comply with the relevant national and applicable international guidelines.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
16.	All payment, reimbursement and medical services to be provided to the research subjects.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
17.	Plans for publication of results – positive or negative- while maintaining the privacy and confidentiality of the study participants.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
18.	Information of other EC approval Status of the study if applicable	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
19.	Details of the study Team	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
20.	Any other information relevant to the study	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

## 2.0 Template for Submission letter

<< On PI/ Institution Letter Head>>>

Date:

To

The Member Secretary

Institutional Ethics Committee

<<Enter Address>>

Ref: <<<..... Protocol Name and Number.....>>>

Sub: <<.....Submission of Study Documents to EC for review and Approval .....>>

Dear Sir/Madam,

Please find enclosed 5 copies of the following documents of the above mentioned project for forthcoming Institutional Ethics Committee (IEC).

<<<<..... List of Documents with version no. and date.....>>>>

I wish to assure you that the study would be initiated at the site only after approval of the Ethic Committee.

Please revert for additional information and clarifications.

Thanking you,

Yours Sincerely,

<<<.... Principal Investigator's Name, Designation .....>>>

Principal Investigator (Protocol Number)

TO WHOM IT MAY CONCERN

We here by confirm the receipt of the above referenced documents submitted to us

---

Signature , Date and Ethics Committee Seal

**3.0 Dispatch Return Log**

<b>Sl. No</b>	<b>Date of Issue</b>	<b>Document Given</b>	<b>Issued To</b>	<b>Signature of receiver</b>	<b>Issued by</b>	<b>Signature</b>	<b>Purpose</b>	<b>Due Date for Return</b>	<b>Returned on date</b>	<b>Received By</b>	<b>Signature</b>

**INSTITUTIONAL ETHICS COMMITTEE PUSHPAGIRI**

**INSTITUTE OF MEDICAL SCIENCES,**

**PUSHPAGIRI RESEARCH CENTRE,**

**Thiruvalla, Kerala-689101, India**

**Ph: 0469 2775518**

**STANDARD OPERATING PROCEDURES**

**Chapter 5**

**AGENDA PREPARATION, MEETING PROCEDURES  
ETHICAL REVIEW AND PREPARATION OF MINUTES OF  
MEETING**

## **CHAPTER 5**

### **AGENDA PREPARATION, MEETING PROCEDURES ETHICAL REVIEW AND PREPARATION OF MINUTES OF MEETING**

#### **1.0 Purpose**

The purpose of this Chapter is to elaborate the administrative process and provide instructions on meeting agenda, review, approval, minutes, and communicating the decision to the Principal Investigator.

The IEC shall review and approve, every research study involving human participants and other forms of studies, before the research is initiated. The IEC shall evaluate the scientific rationale, scope, methodology, and the ethical aspects of the study. The committee shall evaluate the possible risks to the participants with proper justification as well as the expected benefits to participants/community. The adequacy of documentation for ensuring privacy & confidentiality shall also be reviewed.

#### **2.0 Scope**

This Chapter applies to procedures to conduct the IEC meeting:

#### **3.0 Responsibility**

It shall be the responsibility of the respective Member Secretary of IEC and IEC staff to prepare for the IEC meeting.

#### **4.0 Before full board IEC meeting**

Prepare the agenda of the IEC meeting. Schedule studies on the agenda on first come first serve basis. No limit is placed on the number of items on the agenda. The number of items is based on available expertise (members and consultants), urgency, order of submission to the IEC and IEC workload.

#### **Preparation of the meeting**

- The meeting frequency of IEC will be trimonthly.

## *Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

- Reserve the meeting venue for the IEC meeting on the scheduled meeting date and time. The meeting will be held in the Board room of Hospital, unless otherwise specified. Ensure that the room, equipment (projectors, recorder, etc) and facilities are available in good working conditions
- All original files of studies on the agenda are kept in the meeting room for ready reference before the meeting
- Copies of SOPs, Schedule Y, ICMR guidelines are kept available for ready reference
- Secretariat informs the scheduled meeting date and time to the Principal Investigators.

### **Element of review**

The Meeting will be organized in the institution or facility desired by institution. All the members will be signing the attendance sheet. The prepared Agenda will be followed during the meeting .The quorum requirement and conflict of interest will be ensured by the EC Chairperson before discussing the study by any investigator. The Investigator will present the study. Independent Consultants can also be invited to review and advice on a particular topic where EC doesn't have expertise.

The review and the decision will be done based on the below criteria.

- Scientific design and conduct of the study.
- Examination of predictable risks/harms.
- Examination of potential benefits.
- Procedure for selection of subjects: Exclusion/ Inclusion criteria
- Management of research related injuries, side effects, ADRs.
- Compensation provisions.
- Justification for placebo in control arm, if any.
- Availability of products after the study, if applicable.
- Patient information sheet and informed consent form in local language.
- Protection of privacy and confidentiality.
- Involvement of the community, wherever necessary.
- Plans for data analysis and reporting
- Adherence to all regulatory requirements.

The prefilled Documents review checklists will be discussed with the Investigator by the respective EC members. All the queries will be discussed. EC can be go for two types



## *Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

reviews based on the assessment of documents. The Member Secretary/Secretariat shall screen the proposals for their completeness and depending on the risk involved categorize them into two types, namely expedited review, and full committee review

### **Expedited Review**

Proposals that pose no more than minimal risk may undergo expedited review. Such meetings will be conducted by members meeting quorum including Member Secretary and Chairperson

- Research involving clinical documentation materials that are non-identifiable (data, documents, records) Modification or amendment to an approved protocol including administrative changes or correction of typographical errors
- Review of SAE and due analysis report preparation to be sent to CDSCO within 30 days of occurrence of SAE
- Revised proposals previously approved through expedited review, full review or continuing review of approved proposals
- Minor deviations from originally approved research causing no risk or minimal risk;
- Progress/annual reports where there is no additional risk
- Activity limited to data analysis.

Approval granted through expedited review and the decisions of the SAE must be ratified at the next full committee meeting.

### **Full Committee review**

All research proposals presenting more than minimal risk that are not covered under expedited review should be subjected to full committee review, some examples are;

- Research involving vulnerable populations, even if the risk is minimal;
- Research with minor increase over minimal risk
- Studies involving deception of participants
- Amendments of proposals/related documents (including but not limited to informed consent documents, investigator's brochure, advertisements, recruitment methods, etc.) involving an altered risk;

## *Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

- Major deviations and violations in the protocol;
- Any new information that emerges during the course of the research for deciding whether or not to terminate the study in view of the altered benefit–risk assessment;

Research during emergencies and disasters either through an expedited review/ scheduled or unscheduled full committee meetings. This may be decided by Member Secretary depending on the urgency and need.

### **Periodic Review**

All the approved studies will be reviewed atleast once in 6 months from the day of initial approval of the study to understand the progress of the study. All the investigator will be notified the time frame of periodic review via initial approval letter of the study. Intimation notice will be issued by EC office to investigator. The following summary will be reviewed.

- Number of subjects screened
- Number of subjects randomized
- Number of subjects Drop outs
- Number of subjects withdrawn
- List of SAEs
- List of AE
- List of Protocol Deviation
- List of protocol violation
- Any new information relevant to the study

### **Annual Review**

- Approval may be granted for the entire duration of the proposed research or can be subject to annual review depending on the type of study which will be conveyed to researcher at the time of initial review. The researcher should give annual report and request to continue the study with the documents available in the present form. The EC should review the annual report and if found satisfactory IEC will approve to continue the study.

- The first report shall be submitted within thirty (30) days of completion of the year following the date of the first approval. Subsequent reports will be submitted at one-Year intervals following the first report.
- An EC may decide to reverse its positive decision on a study if it receives information that may adversely affect the benefit-risk assessment.

#### **11.0 Review of Protocol Deviation/ Violation**

All Protocol Deviation/Violation/ non-compliance/waiver will have to be notified. All such notifications shall be circulated to IEC members, reviewed & assessed by the committee during the meeting for the seriousness of the deviation / Non-Compliance / Violation with respect to the safety & health aspects of the subjects and the necessary actions shall be taken by the committee accordingly.

#### **Review of Studies involves vulnerable population**

The IEC of Pushpagiri Institute of Medical Sciences and Research Centre takes special consideration in protecting the welfare gives special consideration to protecting the welfare of vulnerable subjects such as children, prisoners, fetuses/neonates, pregnant women, and individuals with consent capacity impairment. The IEC carefully considers group characteristics, such as economic, social, physical, and environmental conditions, to ensure that the research incorporates additional safeguards measures for vulnerable subjects. The IEC may require additional safeguard measures to protect potentially vulnerable population. For instance, the IEC may require that the investigator submit each signed informed consent form to the IEC, that someone from the IEC oversee the consent process, or that a waiting period be established between initial contact and enrollment to allow time to allow the subject time for family discussion and query resolution, family discussion and questions. IEC expects to follow the principals laid down in the ICMR-Ethical Guidelines for Biomedical Research on Human Participant.

#### **RESPONSIBILITY:**

It is the responsibility of the Chairperson and Member-Secretary of IEC to implement, amend and give training to other members of IEC of this SOP.

**PROTOCOL REVIEW PROCESS:**

**DETAILED INSTRUCTION**

**For Pregnant Women, Foetuses:**

Research involving pregnant women and fetuses should involve the least possible risk. The IEC will document specific findings to minimize the potential for risk or harm to the fetus, and additional attention must be given to the conditions for obtaining informed consent. The IEC will ensure that women are not encouraged to discontinue nursing for the sake of participation in research except in the cases where breast-feeding is harmful to the infant. IEC will also ensure that compensation in terms of supplying supplementary food such a milk formula will be considered in such circumstances. In the event of research related to pre-natal diagnostic techniques, IEC will ensure that such research is limited to detect foetal abnormalities or senetic disorders and not for sex determination.

**Research involving Prisoners:**

Prisoners may have a limited ability to make truly voluntary and un-coerced decisions about whether or not to participate as research subject.

**Children involved as subjects/ participants in Research:**

IEC requires special protections for research involving children. Under the regulations, children are persons who have not attained the legal age for consent to treatments or procedures involved in the research under the applicable conducted. The proposed clinical research must fall within one of the four following categories: (i) Clinical Trial not involving Minimal Risk. (ii) Clinical trial involving greater than minimal risk, but presenting the prospect of direct benefits to the individual subjects. (iii) Clinical trial involving greater than minimal risk, yield knowledge that can be generalized about subject's disorder or condition. Clinical trial not otherwise approvable, which presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health and welfare of children. Each category has specific conditions that must be included in their organization Standard Operating Procedures (SOPs) if the institution is involved in human research where children are in the subject population.

**Parental/Legally acceptable representative Permission:**

The IEC require that adequate provisions are made for solicit the permission of each child's parents or guardian/legally acceptable representative. Where parental permission is to be obtained, the IEC will determine whether permission of one parent is sufficient or whether permission must be obtained from both parents in order for the research to be conducted.

**Assent of the Child:**

(a) Provisions must also be made in the protocol to obtain the child's assent when the child is capable of giving assent. (b) IEC may determine that the assent of the child is not necessary if and only if all three of the following conditions are satisfied: (i) The research offers the child the possibility of direct benefit. (ii) The benefit is important to the health or well being of the child. (iii) The benefit is available only in the context of the research. IEC will take great care in approving research where the child is suffering from a life-threatening illness with little real chance of therapeutic benefit from the research. IEC will respect the child's refusal to participate in the research and will be cautious in allowing parents/ legally accepted representatives to overrule. IEC requires assent form is tailored for the child, with respect to his or her level of understanding.

**Clinical trial involving Decisionally Impaired Subjects:**

IEC will consider selection issues, privacy and confidentiality, coercion and undue influence, and risk-benefit analysis. Additional safeguards must be considered by the IEC to protect these subjects.

**Decision-making**

The committee will give its opinion on the project in writing in one of the following ways:

Members will discuss the various issues before arriving at a consensus decision.

- A meeting will be considered valid only if the quorum is fulfilled. This should be maintained throughout the meeting and at the time of decision making. Decisions will be made only in meetings where quorum is complete.
- Only members can make the decision. The expert consultants will only offer their opinions.
- If a member has declared a Conflict of interest (COI) for a proposal then this

## *Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

should be submitted in writing to the Chairperson before beginning the meeting and should be recorded in the minutes.

- The member who has declared COI should withdraw from the EC meeting (leave the room) while the research proposal is being discussed upon. This should be minuted and the quorum rechecked.
- A list of absentee members as well as members leaving or entering in-between the meeting should be recorded.
- Number of proposals reviewed in a meeting should justify that there is ample time devoted for review of each proposal.
- Decision may be to approve, reject or modify the proposals. Specific suggestions should be given for modifications.
- Negative decisions should always be substantiated by appropriate reasons.
- The decision must be taken either by a broad consensus or majority vote and should be recorded. When it is approved unanimously, an approval letter in the prescribed template will be issued and signed by chairman and member secretary. If some members are objecting the study to be approved, chairman will take the voting from the members to see the majority and if majority is there the project will be approved. In that case the voting status also will be mentioned in the approval letter.
- The chairman / member secretary of the committee may provisionally approve without calling a full meeting in case where only administrative amendment has been made.
- This decision will be ratified at the next full committee meeting and minuted.

### **After the IEC meeting**

#### **Preparing the minutes and the decision letters**

- The Member Secretary will compile the proceedings of IEC meeting in a concise and easy-to-read style and will check spelling, grammar and context of the written minutes
- The minutes of the meeting will be compiled within 15 working days. The minutes will record whether the decision was unanimous, or whether a vote was taken for the decision. The number of members voting for, against, and abstaining will be recorded. The disclosure of the IEC member for conflict of interest is recorded in the IEC meeting minutes. The questions and answers

#### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

## *Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

discussed in each meeting will also be discussed.

- The basis for requiring changes in or disapproving research; and a written summary of the discussion of controversial issues and their resolution must be recorded and filed.

### **Approval of the minutes and the decision**

- The minutes of the IEC meeting will be prepared by Member Secretary, IEC or acting member secretary
- The minutes of the IEC meeting will be approved by Chairperson ratified in the subsequent IEC meeting
- The IEC decisions will be communicated to the PIs

### **Filing of the minutes of the meeting**

Place the original version of the minutes in the minutes file and copy of the minutes are filed in the corresponding files of research protocol reviewed in the meeting.

### **Communicating the decision with the investigator**

The decision will be communicated in writing to the PI, preferably within a period of 15 working days of the IEC meeting at which the decision was made. The decision will be communicated through written letter signed by EC member Secretary/ Chairperson. Original letter will be given to the applicant and copy will be maintained with the EC.

## **ANNEXURES**

1. Template for Approval Letter
2. ICD Review Checklist
3. Protocol Review Checklist
4. CTA Review Checklist
5. IB Review Checklist

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

6. Agenda Format
7. Application for Annual Review



a) **Template for EC Approval**

**INSTITUTIONAL ETHICS COMMITTEE**

Date

To,

<<PI Name and project code>>.

Ref: Study Protocol- <<protocol ID and Title>>

Sub: Ethics Committee approval

Dear <<PI Name>>,

The Institutional Ethics Committee, Pushpagiri Institute of Medical Sciences, Pushpagiri Research Centre, Thiruvalla, reviewed and discussed your application dated <<Date of Submission>> to conduct the clinical trial entitled <<Title of the study>> on <<Date of EC meeting held>>.

The following documents were reviewed and approved:

<<List the documents which are reviewed and approved and reviewed only – separately>>

The following members of the Institutional Ethics Committee were present at the meeting held on <<date of EC meeting held>>.

<<List the members name and their role in the IEC in the box below>>

<b>S#</b>	<b>Name</b>	<b>Role in the Ethics Committee</b>
1		
2		
3		

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

4		
5		
6		
7		
8		
9		

Case 1. <<In case study was unanimously approved follow the below pattern>>

The study was unanimously approved with <<Votes in favour write here>> votes in favour of the study. One member was abstained from voting (<<write the name of the members who abstained from voting>>)

Case 2. <<In case study was non-unanimously approved - follow the below pattern>>

The study was unanimously approved with <<Votes in favour write here>> votes in favour of the study as against <<Votes against - write here>> votes against the study. One member abstained from voting (<<write the name of the members who abstained from voting>>).

We confirm that principal investigator did not participate in the deliberations of the ethics committee for this study and did not vote on the proposal for this study.

Please submit the following documents before recruiting the patients in to the study.

<<List the documents which has to be submitted to the IEC before the study to be initiated at our center>>

Please note that you should follow the requirements given below for this study:

- Do not implement any deviation from, or change to, the protocol approved by the IEC without the prior written approval of this ethics committee. Deviations/ changes to the approved protocol may be implemented without prior approval of this ethics

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

committee only when necessary to eliminate immediate hazards to subjects or when changes involve only logistical or administrative aspects of the trial [e.g. change of study monitor(s), telephone numbers(s)].

Promptly report to the IEC:

- Any changes to or deviations to the protocol approved by this ethics committee that you may implement to eliminate hazards to the trial subjects.
- All serious adverse events.
- New information that may affect adversely the safety of the subjects or the conduct of the trial.

Please submit to the IEC, the status report of the study at every 6 months interval.

Please provide a close out report to the Ethics Committee on the completion of the study.

The IEC is organized and operates according to the requirements of ICH - GCP and requirements of the Indian Council of Medical Research (ICMR) and Schedule Y.

Thank you for your time and efforts.

Cordially,

**Member Secretary**

Institutional Ethics Committee

<<Enter Address>>.

<<Name of Chairman>>

Institutional Ethics Committee

<<Enter Address>>.

**b) ICD review Checklist**

Sl.No	Contents	Yes	No	Comments
1.	A statement that the study involves research	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2.	Explanation of the purposes of the research	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3.	Expected duration of subject's participation	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4.	Description of the procedures to be followed, including all invasive procedures	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.	Description of any reasonably foreseeable risks or discomforts to the Subject	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.	Description of any benefits to the Subject or others reasonably expected from research. If no benefit is expected Subject should be made aware of this.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.	Disclosure of specific appropriate alternative procedures or therapies available to the Subject	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8.	Statement describing the extent to which confidentiality of records identifying the Subject will be maintained and who will have access to Subject's medical records	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9.	Trial treatment schedule(s) and the probability for random assignment to each treatment (for randomized trials)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10.	Compensation and/or treatment(s) available to the	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

	Subject in the event of a trial-related injury			
11.	An explanation about whom to contact for trial related queries, rights of Subjects and in the event of any injury	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12.	The anticipated prorated payment, if any, to the Subject for participating in the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13.	Subject's responsibilities on participation in the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
14.	Statement that participation is voluntary, that the subject can withdraw from the study at any time and that refusal to participate will not involve any penalty or loss of benefits to which the Subject is otherwise entitled	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
15.	Any other pertinent information	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16.	Additional elements, which may be required	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16.1	Statement of foreseeable circumstances under which the Subject's participation may be terminated by the Investigator without the Subject's consent.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16.2	Additional costs to the Subject that may result from participation in the study.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16.3	The consequences of a Subject's decision to withdraw from the research and procedures for orderly termination of participation by Subject.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16.4	Statement that the Subject or Subject's representative will be notified in a timely manner	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

	if, significant new findings develop during the course of the research which may affect the Subject's willingness to continue participation will be provided.			
16.5	A statement that the particular treatment or procedure may involve risks to the Subject (or to the embryo or fetus, if the Subject is or may become pregnant), which are currently unforeseeable	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16.6	Approximate number of Subjects enrolled in the study	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
17	Details of Compensation or cost for medical management in case of any Serious Adverse event occurred	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
18	Procedure for consenting AV recording if applicable.			
19	Section for details of Nominee,	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
20	Section for Income and qualification of study subject	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
21	Correctness of the contact details of Investigator and IEC mentioned	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
22	Appropriateness of language used	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**c) Protocol Review Checklist**

<b>Contents</b>	<b>Yes</b>	<b>No</b>	<b>Comments</b>
<b>General Information</b>			
Protocol title	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Protocol identifying number and date	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Any amendment(s) number and date(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Name & Address of the Sponsor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Name & Address of the Monitor (If other than the Sponsor)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Name & Title of the person(s) authorized to sign the protocol for the sponsor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Name & Title of the person(s) authorized to sign the protocol amendment(s) for the sponsor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Name, Title, Address and Telephone number of the sponsor's medical expert for the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Name and title of the investigators	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Address and Telephone number of the trial site(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Name, Title, Address, and Telephone Number of the qualified physician for all trial-site related medical decisions	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Name(s) and address(es) of the clinical laboratory(ies) and other medical and/or technical departments and/or	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

institutions involved in the trial			
<b>Background Information</b>			
Name and description of the IP	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Summary of finding from nonclinical studies that potentially have clinical significance	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Summary of finding from Clinical studies that are relevant to the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description of and justification for the route of administration	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description of and justification for the dosage	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description of and justification for the dosage regimen	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description of and justification for the Treatment period(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A statement that the trial will be conducted in compliance with the protocol, GCP and the applicable regulatory requirement(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description of the population to be studied	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Reference to literature and data that are relevant to the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Trial Objectives and Purpose</b>			
Description about the trial objective	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description about the trial purpose	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Trial Design</b>			



*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

A specific statement of the primary end points to be measured during the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A specific statement of the secondary end points to be measured during the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A description of the type/design of the trial to be conducted (e.g. double blind . placebo- controlled, parallel design)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Schematic diagram of trial design	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Schematic diagram of trial procedures	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Schematic diagram of trial stages	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A description of the measures taken to minimize/ avoid bias	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Blinding	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A description of the trial treatment(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A description of the dosage& dosage regimen of IP	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A description of the dosage form	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A description of the packaging & labelling of the IP	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Expected duration of subject participation	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description of the sequence and duration of all trial periods, including follow-up period	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description of the -Stopping rules   or -discontinuation criterial for individual subjects	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Accountability procedures for IP, Placebo(s) &	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

Comparator(s)			
Maintenance of trial treatment randomization codes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description of procedures for breaking codes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The identification of any data to be recorded directly on the CRF's (i.e. no prior written or electronic record of data)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Selection and Withdrawal of Subjects</b>			
Subject inclusion criteria	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Subject exclusion criteria	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Subject withdrawal criteria (i.e. terminating IP treatment/trial treatment)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description about when and how to withdraw subjects from the trial/IP treatment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description about the type and timing of the data to be collected for withdrawn subjects	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Follow up for subjects withdrawn from IP treatment/trial treatment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Treatment of Subjects</b>			
Name of all the Product(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The dose(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The dosing schedule(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Route/ Mode(s) of administration	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

Treatment period(s) including follow up period(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description about Medication(s)/Treatment(s) permitted (including rescue medication) before and/or during the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description about Medication(s)/Treatment(s) not permitted before and/or during the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Procedures for monitoring subject compliance	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Assessment of Efficacy</b>			
Specification of efficacy parameters	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Methods and timing for assessing of efficacy parameters	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Methods and timing for recording of efficacy parameters	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Methods and timing for analyzing of efficacy parameters	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Assessment of Safety</b>			
Specification of safety parameters	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Methods and timing for assessing of safety parameters	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Methods and timing for analyzing of safety parameters	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Procedures for eliciting reports of AE and Intercurrent illnesses	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Procedures for recording& reporting of AE and Intercurrent illnesses	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

Description about the type and duration of the follow-up of subjects after AE	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Statistics</b>			
Description of the statistical methods to be employed, including timing of any planned interim analysis(es)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
No of subjects planned to be enrolled in whole study	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
In multicenter trials, no: of enrolled subjects projected for each trial site	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Reason for choice of sample size, including reflections on (or calculations of) the power of the trial and clinical justification	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The level of significance to be used	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Criteria for the termination of the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Procedure for accounting for missing data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Procedure for accounting for unused data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Procedure for accounting for spurious data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Procedure for reporting any deviation(s) from the original statistical plan	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Description about the selection of subjects to be included in the analyses (e.g. all randomized subjects, all dosed subjects, all eligible subjects, evaluable subjects)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Direct Access to Source Data/Documents</b>			

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

Surety from sponsor that it is specified in the protocol or other written agreement that the investigator(s) / Institution(s) will permit trial-related audits, providing direct access to source data/documents	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Surety from sponsor that it is specified in the protocol or other written agreement that the investigator(s) / Institution(s) will permit trial-related IRB/IEC review, providing direct access to source data/documents	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Surety from sponsor that it is specified in the protocol or other written agreement that the investigator(s) / Institution(s) will permit trial-related regulatory inspection(s), providing direct access to source data/documents	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Quality control and Quality Assurance</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Ethics</b>			
Description of ethical considerations relating to the trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Data Handling and Record Keeping</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Financing and Insurance</b>			
Details about Finance and insurance, if not addressed in a separated agreement	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Publication Policy</b>			
Details about Publication Policy, if not addressed in a separated agreement	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Supplements</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**d) Clinical Trial Agreement Review Checklist**

<b>Sl No</b>	<b>Content</b>	<b>Yes</b>	<b>No</b>	<b>Comment</b>
<b>1</b>	Sponsor's name	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>2</b>	Type of Agreement Tripartite or Quadripartite	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>3</b>	The venue of Jurisdiction mentioned?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>4</b>	Insurance certificate reviewed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>5</b>	Indemnity clauses are favourable to the institution?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>6</b>	Check for the compensation details	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>7</b>	Details of SAE management is mentioned?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>8</b>	Financial funding for the project is mentioned?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>9</b>	Any other legal implication for the institution and investigator	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>10</b>	Subjects rights will be protected?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

e) IB Review Checklist

Sl.No	Contents	Yes	No	Comments
1.1	Sponsor's name	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1.2	The reference number allocated to the study	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1.3	The identity of investigational product (i.e. research number, chemical or approved generic name, and trade name(s) where legally permissible and desired by the sponsor)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1.4	Edition number and date	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1.5	Reference to the number and date of the edition it supersedes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>2.</b>	<b>Confidentiality statement</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>3.</b>	<b>Table of Contents</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>4.</b>	<b>Introduction</b>			
4.1	Information relevant to the stage of clinical development including the significant physical & chemical properties, pharmaceutical, pharmacological (pharmacological class, advantages over other substances in that class and rationale for performing the proposed study), toxicological, pharmacokinetic, metabolic, and clinical information (anticipated prophylactic/ therapeutic or diagnostic indication(s)) of all active ingredients	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4.2	The introductory statement - The general approach to be followed in evaluating the Investigational Product	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>5</b>	<b>Physical, Chemical, and Pharmaceutical Properties and Formulation parameters</b>			
5.1	A description about the Investigational Product substance(s), including the chemical and / or structural formula(e)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.2	A brief summary of the relevant physical, chemical and pharmaceutical properties.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.3	Information about the structural similarities to other known compounds	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.4	Information about excipients	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.5	Information about storage and dosage handling	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**Standard operating procedure**

Pushpagiri Institute of Medical Sciences,

Pushpagiri Research Centre, Thiruvalla

Version : 1.0 Dated:20<sup>th</sup> Nov 2019

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

6.1	Information about data relating to non-clinical pharmacology, pharmacokinetics, metabolism profile in animals and toxicology	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.2	Summary of all relevant non-clinical pharmacology, toxicology, pharmacokinetic, and the Investigational Product metabolism studies	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.3	Summary of the methodology used,	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.4	The results and a discussion of the relevance of the findings to the investigated therapeutic effects besides the possible unfavourable effects in humans.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.5	Information about the species used	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.6	Information about number and sex of animals in each group	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.7	Information about Unit dose (mg/kg)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.8	Information about dose interval	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.9	Information about route of administration	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.10	Information about duration of dosing	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.11	Information on systemic distribution	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.12	Information about duration of post-exposure follow-up	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13	<b>Results</b>			
6.13.1	Nature and frequency of pharmacological or toxic effects	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.2	Severity or intensity of pharmacological or toxic effects	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.3	Time to onset of effects	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.4	Reversibility of effects	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.5	Duration of effects	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.6	Dose response	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.7	Dose response of observed effects	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.8	The relevance to humans	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.9	Any aspects to be studied in humans	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.10	Comparison of the effective and non-toxic dose findings in the same animal species (i.e. The therapeutic index should be discussed)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.11	The relevance of this information to the proposed human dosing	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.13.12	Comparisons made in terms of blood/tissue levels rather than on a mg/kg basis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.14	<b>Non-clinical Pharmacological (Pharmacodynamics)</b>			
6.14.1	A summary of the pharmacological aspects of the	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>



	investigational product and its metabolites studied in animals			
6.14.2	Potential therapeutic activity assessment (e.g. efficacy models, receptor binding, and specificity)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.14.3	Safety assessment (eg. special studies to assess pharmacological actions other than the intended therapeutic effect(s)).	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>6.15</b>	<b>Pharmacokinetics and Product Metabolism in Animals</b>			
6.15.1	A summary of the pharmacokinetics and biological transformation and disposition of the investigational product in all species Studied	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.15.2	Discussion of the findings about the absorption and the local and systemic bioavailability of the IP and its metabolites	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.15.3	Investigational product and its metabolites relationship to the pharmacological and toxicological findings in animal species.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>6.16</b>	<b>Toxicology</b>			
6.16.1	A summary of the toxicological effects of IP found in relevant studies conducted in different animal species	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.16.2	Single dose	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.16.3	Repeated dose	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.16.4	Carcinogenicity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.16.5	Special studies (eg. irritancy and sensitisation)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.16.6	Reproductive toxicity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6.16.7	Genotoxicity (Mutagenicity)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>7</b>	<b>Effects in Humans</b>			
7.1	Discussion of the known effects of the investigational product(s) in humans	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.2	Information on pharmacokinetics, metabolism, Pharmacodynamics, dose response, safety, efficacy, and other pharmacological activities	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.3	Brief summaries of other clinical studies conducted on the same product	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>7.4</b>	<b>Pharmacokinetics and Product Metabolism in Humans</b>			
7.4.1	A summary of information on the pharmacokinetics of the investigational product(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.4.2	Pharmacokinetics (including metabolism, as appropriate, and absorption, plasma protein binding, distribution, and elimination)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.4.3	Bioavailability of the investigational product	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

	(absolute, where possible, and/or relative) using a reference dosage form			
7.4.4	Population subgroups (e.g. gender, age, and impaired organ function).	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.4.5	Interactions (e.g. Product-product interactions and effects of food)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.4.6	Other pharmacokinetic data (e.g. results of population studies performed within clinical trial(s).	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>7.5</b>	<b>Safety and Efficacy</b>			
7.5.1	Information about the Investigational Product (s)* (including their metabolites, where appropriate) safety Pharmacodynamics	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.5.2	Information about the Investigational Product(s)* (including their metabolites, where appropriate) efficacy and dose response(s) that were obtained from preceding trials in humans (healthy volunteers and/or patients)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.5.3	In cases where a number of clinical studies have been completed, the use of summaries of safety and efficacy across multiple trials by indications in subgroups may provide a clear presentation of the data.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.5.4	Tabular summaries of adverse drug reactions for all the clinical trials (including those for all the studied indications)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.5.5	Important differences in adverse drug reaction patterns/incidences across indications or subgroups	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.5.6	A description of the possible risks and adverse drug reactions to be anticipated based on prior experiences with the product under investigation and with related products.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7.5.7	A description about the precautions or special monitoring to be done as part of the investigational use of the product(s).	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>8</b>	<b>Regulatory &amp; Post-marketing Experiences</b>			
8.1	Countries where the investigational product has been marketed or approved.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8.2	Any significant information arising from the marketed use should be summarised (eg. formulations, dosages, routes of administration, and adverse product reactions)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

*Chapter 5 : Agenda Preparation, Meeting Procedures Ethical Review And Preparation Of Minutes Of Meeting*

8.3	Countries where the investigational product did not receive approval/registration for marketing or was withdrawn from marketing/registration.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>9</b>	<b>Summary of Data and Guidance for the Investigator</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10	<b>Bibliography</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10.1	Overall discussion of the non-clinical and clinical data	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10.2	The information from various sources on different aspects of the investigational product(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10.3	Published reports on related products	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10.4	The information given in this section should provide the investigator with a clear understanding of the possible risks and adverse reactions.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10.5	Guidance about recognition and treatment of possible overdose and adverse drug reactions.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**f) Agenda Format**

**AGENDA OF IEC MEETING**

Meeting No :

Location of IEC Meeting :

Meeting date:

Meeting Time:

The Board meeting will proceed in the following sequences:

Period1:

Discussion of the points arising from the minutes of the previous meeting and presentation of agenda of the day's meeting and Declaration of Conflict.

Period2:

A] New Protocol Presentation, Review, Discussion and reaching a decision by voting to approve /raise queries,

B] Review the responses forwarded by the principal investigator to the query letter/ resubmitted protocols

C] Approve protocol amendment and related documents.

D] To review the continuing review report / completion report / final clinical trial report/ Annual report / Termination reports.

E] To review Protocol Deviations /Violations

F] To review other Letters related to projects to review Monitoring reports

G] To inform about the IEC meeting and to review the policy decisions

H] To inform about the SAE Subcommittee meetings and to review SAE / Safety reports.

I] Other points for discussion\_

Period3:

Issues reviewed and approved by the IEC member Secretary and Chairperson which are to be reported Secretary and Chairperson which are to be reported for Consideration

Period4:

Issues to be informed to the members at Full Board which are approved by the IEC member Secretary and Chairperson and letters already sent to the principal investigator

Period5:

Other issues based on the interest of members

**g) Application For Renewal Of Approval**

**APPLICATION FOR RENEWAL OF APPROVAL**

- IEC Reference number
- Title of the research proposal
- Name of the Principal Investigator (PI) with qualification and designation
- Approval date
- Date study initiated, if no, specify reason
- Has subject recruitment begun?
- If subject recruitment has not begun, give reasons
- How many subjects have been screened?
- How many subjects have been randomized?
- How many Screen failures and or drop outs? Reason
- Is subject recruitment continuing?
- Is the Subjects completed the study, if no number of pending visits.
- Expected date for study completion?
- Have there been any adverse events/ Serious Adverse Events? If yes, give details
- Any Protocol deviation/Violations?
- Have there been any unanticipated study-related problems? If yes, give details.
- List of attachments for review, if any
- Remarks, if any

Signature of the Principal Investigator with date.

**NOTE**

- Investigator can use own format, but all the information should be furnished.
- Investigator should attach the renewal fee along with the application.

**INSTITUTIONAL ETHICS COMMITTEE**  
**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**  
**PUSHPAGIRI RESEARCH CENTRE,**

Thiruvalla, Kerala-689101, India

**Ph: 0469 2775518**

**STANDARD OPERATING PROCEDURES**

**Chapter: 6**

**SITE MONITORING**

**Chapter : 6**

**SITE MONITORING**

**1.0 Purpose**

The purpose of this chapter is to provide the procedures for site monitoring.

**2.0 Scope**

This Chapter applies to conducting monitoring of studies involving human subjects at intervals appropriate to the degree of risk but not less than once a year. Depending upon the degree of risk to the participants, the nature of the study, the vulnerability of the study participants and duration of the study, IEC shall choose to monitor the study more frequently.

**3.0 Responsibility**

ECs shall follow mechanisms to monitor the approved study site until completion of the research to check for compliance or improve the function. Monitoring can be routine or –for cause and shall be decided at a full committee meeting. For research that involves higher risk or vulnerable participants or if there is any other reason for concern, the EC at the time of initial review or continuing review shall suggest that routine monitoring may be conducted at more frequent intervals.

The frequency of monitoring shall be decided during the initial review of the meeting among the EC Members. The monitoring will be done by the Monitoring committee nominated by Chairperson and Member Secretary.

**Procedure**

This includes review of the overall progress of each study to insure the safety of participants, validity of data, that the projected actual goals are met on a timely basis, eligibility and evaluability rates do not fall below minimum acceptable standards, risks are not excessive, adverse events are appropriately monitored and reported to the appropriate agencies. Inherent in this process is the goal of enhancing the quality of the research.

The Cause for monitoring will be performed based on the following criteria

- High number of protocol violations and deviations;
- Large number of proposals carried out at the study site or by the same researcher;
- Large number of SAE reports;
- Complaints received from participants;
- Non-compliance with EC directions;
- Misconduct by the researcher

### **5.0 Before the Visit**

The EC Secretariat will inform the investigator about the monitoring visit date. The monitoring committee will inform the investigator about the agenda of the monitoring visit.

### **During the Visit**

The monitoring will be done by using the checklist and report will be submitted to the EC Chairperson and member secretary. The report will be discussed in the next full quorum EC Meeting. Monitor should give special attention to right safety well-being of study subjects while reviewing the study documents.

The following objectives are followed while monitoring the study.

- Eligibility of subjects recruited
- Proper recording and reporting of AE and SAE
- Adequate Consent procedure are followed
- Ongoing informed consent procedure is in place
- Adherence to protocol and regulatory requirements
- Investigational Product storage and handling

### **7.0 After the Visit**

Monitoring visit checklist will be filled and submit to the IEC secretariat within 14 days. The report will be discussed in the next full board meeting of IEC. The findings and recommendations from IEC will be communicated to the Principal investigator 14 days after the meeting



**ANNEXURES**

1. Monitoring checklist
2. Monitoring Visit report template

**a) Monitoring Checklist**

<b>MONITORING CHECKLIST</b>	
Monitoring Visit	Date of the Visit:
Study Title:	
Principal Investigators:	Phone:
Institute:	Address:
Sponsor:	Address:
Total number of expected subjects:	Total subjects Enrolled:
Are site facilities appropriate?  <input type="checkbox"/> Yes <input type="checkbox"/> No	Comment:
Are Informed Consents recent? Check about the ongoing informed consent process.	Comment:
In case of AV consenting, are the video films taken and stored appropriately?	Comment:
Check all the subject has got ample time for consenting.	Comment:
Any Adverse Events found?	Comment:

*Chapter 6 : Site Monitoring*

Any protocol Non-Compliance /violation?	Comment:
Are all Case Record Forms up to date?	Comment:
Are storage of data and investigating products locked?	Comment:
How well are participants protected?	Comment:
Any outstanding tasks or results of visit?	Comment:
Duration of visit: .....hours	Starting from:_____Hrs  Finish: _____Hrs
Name of IEC/member/  Representatives and Accompanying person:	
Completed by:	Date:

**b) Template for Monitoring visit report**

<b>MONITORING VISIT REPORT</b>	
<b>Name of the Study:</b>	
<b>Name of sponsor:</b>	
<b>Study Drug:</b>	
<b>Protocol ID:</b>	
<b>Name of the Investigator:</b>	

Chapter 6 : Site Monitoring

<b>Site ID:</b>	
<b>Contact Details of Investigational Site</b>	
<b>Visit Date:</b>	

<b>Site personnel present</b>	<b>Function</b>

<b>S.No.</b>	<b>Concerns / Issues/ Situations</b>	<b>Comments / Resolutions</b>	<b>Answer from the concerned personnel</b>	<b>Sign</b>	<b>Date</b>
<b>1</b>	<b>SMF Review</b>				
<b>2</b>	<b>ICD Review</b>				
<b>3</b>	<b>CRF Review</b>				
<b>4</b>	<b>Site Facility Inspection</b>				

*Chapter 6 : Site Monitoring*

<b>5</b>	<b>Source Data Verification</b>				
<b>6</b>	<b>AE / SAE Review</b>				
<b>7</b>	<b>Other Issues</b>				

**Comments from PI team:**

---

**Approvals / Signatures**

This signature confirms that this report summarizes the actions and observations at the site audit visit.

Type of Monitoring  Prepared By:  Name :  Designation:  Sign & Date:	Approved By:  Name :  Designation:  Sign & Date:
--	--

**INSTITUTIONAL ETHICS COMMITTEE**  
**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**

**PUSHPAGIRI RESEARCH CENTRE,**

Thiruvalla, Kerala-689101, India

Ph: **0469 2775518**

**STANDARD OPERATING PROCEDURES**

**Chapter 7**

**PROTECTION OF SUBJECT RIGHT SAFETY AND WELL-  
BEING**

## **CHAPTER 7**

### **PROTECTION OF SUBJECT RIGHT SAFETY AND WELL-BEING**

#### **1.0 Purpose**

This Chapter shall provide guidelines for dealing with and accommodating requests by participants/patients regarding their rights as a participant or to resolve their complaints in any approved research study.

#### **2.0 Scope**

This Chapter shall apply to all requests concerning the rights and well-being of the research participants participating in studies approved by the IEC.

#### **Responsibility.**

It shall be the responsibility of the IEC Member Secretary to provide the required information to the research participants/ research participant's representatives/patient, in the case of queries received.

It shall be the responsibility of the Member Secretary/Chairperson to initiate a process of giving information to the participants or identifying and addressing any injustice that has occurred, if complaints are received from research participants.

The IEC shall assess the adequacy of safeguarding of the rights and welfare of research participants, and the appropriate inclusion of women, minorities, and children, based on the information in the application.

The IEC shall evaluate the involvement of human subjects and proposed protections according to the following review criteria:

- Risk to subjects.
- Adequacy of protection against risks.
- Potential benefits of the proposed research to the subjects and others.
- Importance of the knowledge to be gained.
- Required qualifications and experience of the Investigators for the proposed study

## *Chapter 7 : Protection Of Subject right safety And well-being*

- Any plans to withdraw or withhold standard therapies for the purpose of the research and the justification for such action.
- Plans to withdraw subjects from the study by the Investigator.
- Medical care to be provided to research participants during and after the course of the research.
- Adequacy of medical supervision and social support for the research participants.
- Steps to be taken if research participants voluntarily withdraw during the research.
- Arrangements, if appropriate, for informing the research participant's general practitioner or family doctor, including procedures for seeking the participant's consent to do so.
- Description of any plans to make the study product available to the research participants following the research and description of any financial costs to the research participants.
- Compensations for research participants for attending the visits.
- Provisions for compensation/treatment in the case of the injury/ disability/ death of a research participant attributable to participation in the research.
- Insurance and indemnity arrangements.
- Translations for appropriateness of language, accuracy and completeness of information.

The adequacy of the above points shall be ensured by proper review and monitoring by the EC.

A description of the information shall be given to participants and the persons who will have access to personal data of the research participants, including medical records and biological samples; and measures shall be taken to ensure the confidentiality and security of personal information concerning research participants.

In addition to that IEC office shall have the complaint register forms (Annexure 1) available for subjects who can fill their complaint and furnish in the complaint box. The subjects can also call to the EC contact details provided in their complaint and register the complaint. The EC office shall keep a register (Annexure 2) for the same and communicate with the institution and investigator to resolve it. The resolution shall be discussed and communicated to the subject.

### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

**ANNEXURES**

1. Subject complaint form
2. Register template

**1.0 Subject complaint form**

<b>SUBJECT COMPLAINT FORM</b>	
Institutional Ethics Committee Address Contact person: Contact number : Email	
Name of the subject: Address : Contact Number: Email ID: Name of the Bystander: Contact Number:	
Name of the Principal Investigator: Name of the study:	
Brief Description of the complaint:	
Sign and Date:	
Received By	
Signature:	



2.0 Subject Complaint Register

SI No	Name of the subject	Name of the Study	Name of the Principal Investigator	Date of complaint registered	Nature of Complaint	Action Taken	Mode of resolution	Date of resolution

**INSTITUTIONAL ETHICS COMMITTEE**  
**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**  
**PUSHPAGIRI RESEARCH CENTRE,**  
**Thiruvalla, Kerala-689101, India**

**Ph: 0469 2775518**

**STANDARD OPERATING PROCEDURES**

**Chapter 08**

**ADMINISTRATIVE SUPPORT FOR EC**

## **CHAPTER 08**

### **ADMINISTRATIVE SUPPORT FOR EC**

#### **1.0 Purpose**

Purpose of this Chapter shall be to provide guidance for the administrative support for the functioning of IEC including financial support and resources.

#### **2.0 Scope**

This Chapter applies to the administrative support being received by IEC.

#### **3.0 Administrative Support**

The institution shall be responsible for establishing an EC to ensure an appropriate and sustainable system for quality ethical review and monitoring. The institution shall be responsible for providing logistical support, such as infrastructure, staff, space, funds, adequate support and time for the Member Secretary to run the EC functions.

The institution shall provide space, infrastructure and staff to the EC for maintaining a full-time secretariat, safe archival of records and conduct of meeting. The selection criteria for administrative support staff shall be based on the qualification and experience as decided by the institution.

#### **Financial Operations**

- Ethics committee can be financially supported by the Institution. Every institution shall allocate reasonable funds for smooth functioning of the EC
- A reasonable fee for review may also be charged by the EC to cover the expenses related to optimal functioning in accordance to Institutional policies.
- The income and expenditure of the ethics committee shall be documented in the Income Expense Ledger Book.

## *Chapter 8 : Administrative Support for EC*

- The income and expenditure shall be audited by audit committee of Ethics committee once in a year. The audit report shall be submitted to the Head of Institution and EC chairperson
- Member Secretary shall be responsible for maintaining the finance records
- Member Secretary shall report to the Head of the Institution the income and expenditure report biannually.
- The fees charged by the EC for the review of applications as mentioned in the EC Fee SOP is mentioned in the Annexure. (Annexure 1)

### **Honorarium to EC Members**

- It is recognized that all the Members of EC are busy individuals in their own positions. They, by all means, take time to review the protocol and attend the meeting.
- For balancing the sensitivity of their time on one hand & also not to be coercive in nature by furnishing undue amounts, it is decided that a nominal amount would be paid as compensation/reimbursement to each member who would attend a meeting.
- This amount would also serve as their travel allowance, to & from the meeting venue and other incidentals that the members may spend on account of the meeting.
- The Secretariat staff would be ready with the payments to be paid to the members by cheque/cash, after a meeting. (Annexure 2)

The Members who attended a meeting shall:

1. Sign the attendance sheet.
2. Return all the documents circulated to the members for preparation for the review for the meeting.
3. Sign the Dispatch and Return Log of Documents reflecting the above.

*Page / 102*

### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla

*Version : 1.0 Dated:20<sup>th</sup> Nov 2019*

*Chapter 8 : Administrative Support for EC*

4. Sign the Payment Receipt Voucher for receipt of the compensation of the meeting held.
5. Receive the payment as per the Payment Receipt Voucher for their contribution in the meeting.

**ANNEXURES**

1. EC Fee Annexure
2. Payment receipt voucher

1.0 EC Fee Annexure

Bank Name	.....
Payee Name	.....
Pan No	.....
Account NO	.....
IFSC Code	.....
Initial Review Fees for Phase II, III & IV Clinical Trials	.....
Review fees for the amendment of approved documents	.....
SAE Review Fee	.....
Expedited review fee	.....
Annual Fee	.....

**2.0 Payment Receipt Voucher**

Date: \_\_\_\_\_

	Rs	P
Paid To: _____		
Particulars: _____ _____		
Rupees: _____		

Authorized by: \_\_\_\_\_

Passed by : \_\_\_\_\_

Paid cash/ Cheque drawn on: \_\_\_\_\_

Cheque No: \_\_\_\_\_ Date: \_\_\_\_\_

Receiver's Signature

**INSTITUTIONAL ETHICS COMMITTEE**

**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**

**PUSHPAGIRI RESEARCH CENTRE,**

Thiruvalla, Kerala-682012, India

Ph: **0469 2775518**

**STANDARD OPERATING PROCEDURES**

**CHAPTER 09**

**COMMUNICATION WITH STAKE HOLDERS**

**CHAPTER 09**

**COMMUNICATION WITH STAKE HOLDERS**

**1.0 Purpose**

Purpose of this chapter to give guidance on the communication process with the Head of Institution, Investigator and Regulatory.

**2.0 Scope**

This Chapter applies to the communication process for IEC with various stake holders.

**Communication with Regulatory**

The IEC is registered under Drug controller General of India.

IEC communicate with DCGI on the following topics

- In the contest of revision SOP and constitution of IEC members
- Reregistration process of IEC
- Communicating due analysis report of SAE occurred at the institution
- Any other relevant communication receive from DCGI

**Communication with the investigator**

IEC will communicate with investigator in writing and same will be documented. The IEC communicates with investigator in following contests

- Receipt acknowledgment for all communication from the investigators
- Reminder for the annual reports, annual review, periodic reports or any other relevant communication expect from investigator
- Deliberations of the meeting via approval letter, disapproval letter or query letter
- Monitoring intimations and monitoring findings
- Any additional information IEC requires regarding the study.



## Communication with the Head of Institution

IEC is constituted under the HOI and report to the HOI timely manner. The communication will be through email or writing. Below are the common reporting procedures to HOI.

- Resignation and replacement of members
- Annual assessment of members
- Annual Audit report of EC functioning
- Biannual report from Member secretary regarding overall functioning and finance arrangements.
- Reconstitution and approval of revision of SOP
- Administrative requirements

### Annexure

#### 1. Reminder letter to investigator

<b>Reminder letter to investigator</b>	
Name of Principal Investigator: -	
Study Title	
The above-referenced project was approved by the IEC on_ and is due for _____ by the IEC.	
Kindly submit the continuing review application on or before_____. In case the projects have been completed/terminated, kindly complete the appropriate forms and submit to IEC on or before (date).	
Thanking you for your co-operation,	
Yours truly,	
Signature with date	
Member Secretary	

### Standard operating procedure

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

**INSTITUTIONAL ETHICS COMMITTEE**

**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**

**PUSHPAGIRI RESEARCH CENTRE,**

Thiruvalla, Kerala-689101, India

Ph: **0469 2775518**

**STANDARD OPERATING PROCEDURES**

**Chapter : 10**

**REVIEW OF SERIOUS ADVERSE EVENT AND OTHER  
SAFETY REPORTS**

## **CHAPTER 10**

### **REVIEW OF SERIOUS ADVERSE EVENT AND OTHER SAFETY REPORTS**

#### **1.0 Purpose**

Purpose of this chapter shall be to give the guidance for the review and reconciliation of Serious Adverse events reporting to the IEC.

#### **2.0 Scope**

This SOP chapter shall apply to the IEC review of SAEs and unexpected events reports including follow up reports submitted by investigators.

#### **3.0 Responsibility**

The IEC shall be responsible for the review of all adverse events happening in the study. All AEs shall be recorded and reported to the EC according to a pre-planned timetable depending on the level of risk and as recommended by the EC. EC shall give more attention while reporting and reviewing Serious Adverse Events (SAE). The EC shall be responsible for reviewing the relatedness of the SAE to the research, as reported by the researcher, and determining the quantum of compensation and type of assistance to be provided to the participants.

#### **4.0 Definition of Serious Adverse Event (SAE)**

Any untoward medical occurrence that at any dose:

- results in death,
- is life-threatening,
- requires inpatient hospitalization or prolongation of existing hospitalization,
- results in persistent or significant disability/incapacity, or
- is a congenital anomaly/birth defect.

#### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

All clinical trials under the purview of CDSCO, the timeline and procedures as notified from time to time shall be followed for SAE reporting. All research participants who suffer harm, whether related or not, shall be offered appropriate medical care, psycho-social support, referrals, clinical facilities, etc. Medical management shall be free if the harm is related to the research. Compensation shall be given to any participant when the injury is related to the research. This shall be applicable to participants in any of the arms of research, such as intervention, control and standard of care.

### Procedure for reporting SAE

- Investigators who are participating in the clinical trial from the Institution shall be requested to strictly follow the reporting and review guidelines of the SAE as per the local regulations of the country.
- As per the regulation Investigator has to submit the initial report of SAE to EC within 24 hours of SAE occurrence. Investigator can submit the SAE report to EC via an email followed by hard copy. The reporting should make via Appendix XI form along with supportive documents.

Ethics committee E-mail ID for 24-hr SAE submission	
Ethics committee Email:	<b><u>pushpagiriirb@pushpagiri.in</u></b>
Ethics committee contact number	<b>0469 2775518</b>

- The investigator has to submit the initial report of SAE to the respective sponsor within 24 hours of SAE occurrence.
- The investigator has to submit the initial report of SAE to the Drug Controller General of India within 24 hours of SAE occurrence at the below mentioned Email ID/Fax No.

Higher Authority E-mail ID and Fax No. for 24-hr SAE submission	
Higher Authority Email:	<b><u>dci@nb.nic.in</u></b>
Higher Authority Fax No:	<b>01123236973</b>

### Standard operating procedure

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

- The Investigator and Sponsor have to submit the analyzed report of SAE to the EC Chairman, Head of the Institution and DCGI within 14 calendar days of SAE occurrence.
- On receipt of the analyzed report of SAE from the Investigator, the EC shall organize a full quorum meeting and request the investigator to present about the event. The committee shall discuss about the relatedness of the event with the clinical trial and give opinion on financial compensation to be paid by the Sponsor/ his representative according to the formula published by DCGI.
- A detailed report of recommendation of compensation shall be submitted to the DCGI by EC within 30 calendar days of SAE occurrence.
- If the SAE is death the report shall be submitted to the Chairman of Expert Committee as well within the above-mentioned time frame.

***Any injury or death due to the following reasons shall be considered as clinical trial related injury or death and subjects are entitled to receive the compensation.***

- a) Adverse effect of investigational product***
- b) Violation of approved protocol, scientific misconduct or negligence by sponsor or sponsor representative or investigator***
- c) Failure of investigational product to provide intended therapeutic effect***
- d) Use of placebo in placebo-controlled trial***
- e) Adverse effect due to concomitant medication excluding standard of care necessitated as part of approved protocol***
- f) For injury to child in utero due to parent's participation in clinical trial***
- g) Any trial related procedures involved in the study***

While deliberating on the quantum of compensation to be awarded to participants who have suffered research-related injury, the EC shall consider aspects including the type of research (interventional, observational, etc.), extent of injury (temporary/permanent, short/long term), loss of wages, etc. For other sponsored research, shall be the responsibility of the sponsor (whether a pharmaceutical company, government or non-governmental organization (NGO), national or international/bilateral/multilateral donor

agency/institution) to include insurance coverage or provision for possible compensation for research-related injury or harm within the budget.

**Compensation in case of injury or death during clinical trial:**

- In the case of an injury occurring to the clinical trial subject, he or she shall be given free medical management as long as required or till it is established that the injury is not related to clinical trial whichever is earlier.
- In case the injury occurring to the trial subject is related to the clinical trial, such subject shall also be entitled for financial compensation as per order of the licensing authority defined under clause (b) of rule 21, and the financial compensation shall be over and above any expenses incurred on the medical management of the subject.
- In the case of clinical trial related death of the subject, his/her nominee(s) shall be entitled for financial compensation, as per the order of the licensing authority defined under clause (b) of rule 21, and the financial compensation shall be over and above any expenses incurred on the medical management of the subject.
- The expenses on medical management and the financial compensation in the case of clinical trial injury or death of the trial subject shall be borne by the sponsor of the clinical trial.
- The financial compensation for clinical trial related injury or death could be in the form of
  - Payment for medical management;
  - Financial compensation for trial related injury;
  - Financial compensation to nominee(s) of the trial subject in case of death;
  - Financial compensation for the child injured in—utero because of the participation of parent in a clinical trial.
- Any injury or death of the subject occurring in clinical trial due to following reasons shall be considered as clinical trial related injury or death and the subject or his/her

nominee(s), as the case may be, shall be entitled for financial compensation for such injury or death:

- Adverse effect of investigational product(s);
  - Violation of the approved protocol, scientific misconduct or negligence by the sponsor or his representative or the investigator;
  - Failure of investigational product to provide intended therapeutic effect;
  - Use of placebo in a placebo-controlled trial;
  - Adverse effects due to concomitant medication excluding standard care, necessitated as part of approved protocol;
  - For injury to a child in-utero because of the participation of parent in clinical trial;
  - Any clinical trial procedures involved in the study.
- The Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for the conduct of the clinical trial, shall provide financial compensation, if the injury or death has occurred because of any of the above reasons.
  - The Sponsor, whether a pharmaceutical company or an institution shall give an undertaking along with the application for clinical trial permission to the licensing authority defined in clause (b) of Rule 21, to provide compensation in the case of clinical trial related injury or death for which subjects are entitled to compensation.
  - In case the sponsor fails to provide medical management for the injury to the subject and/or financial compensation to the trial subject for clinical trial related injury or financial compensation to the subject's nominee(s) in case of clinical trial related death of the subject, the licensing authority may after giving an opportunity to show cause why such an order should not be passed, by an order in writing, stating the reasons thereof, suspend or cancel the clinical trial and/ or restrict sponsor including his representative(s) to conduct any further clinical trials in the country or take any other action deemed fit under the rules.

**Procedure for payment of financial compensation:**

The Investigator shall report all serious and unexpected adverse events to the Licensing Authority as defined under clause (b) of rule 21, the Sponsor or his representative whosoever had obtained permission from the Licensing Authority for conduct of the Clinical trial and the Ethics Committee that accorded approval to the study protocol, within twenty-four hours of their occurrence as per Appendix XI.

**The cases of serious adverse events of death shall be examined as given below:**

- a. An independent Expert Committee shall be constituted by the Licensing Authority as defined under rule 21(b) to examine the cases and recommend to the Licensing Authority for the purpose of arriving at the cause of death and quantum of compensation in case of clinical trial related death.
- b. The Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conducting the clinical trial, and the Investigator shall forward their reports on serious adverse event of death after due analysis to Chairman of the Ethics Committee and Chairman of the Expert Committee with a copy of the report to the Licensing Authority as defined under rule 21(b) and the Head of the Institution where the trial has been conducted, within ten calendar days of occurrence of the serious adverse event of death.
- c. The Ethics Committee shall forward its report on serious adverse event of death after due analysis along with its opinion on the financial compensation, if any, to be paid by the Sponsor or his representative, whosoever had obtained permission from the Licensing Authority as defined under rule 21(b) for conducting the clinical trial, to the Chairman of the Expert Committee with a copy of the report to the Licensing Authority within 30 days of the occurrence of the serious adverse event of death.



## *Chapter 10: Review Of Serious Adverse Event And Other Safety Reports*

- d. The Expert Committee shall examine the report of serious adverse event of death and give its recommendations to the Licensing Authority for the purpose of arriving at the cause of the adverse event within thirty days of receiving the report from the Ethics Committee, and the Expert Committee while examining the event, may take into consideration, the reports of the Investigator, Sponsor or his representative whosoever had obtained permission from the Licensing Authority for conducting the clinical trial and the Ethics Committee.
- e. In the case of clinical trial related death, the Expert Committee shall also recommend the quantum of compensation to be paid by the Sponsor or his representative, whosoever had obtained permission from the Licensing Authority as defined under rule 21(b) for conducting the clinical trial.
- f. The Licensing Authority shall consider the recommendations of the Expert Committee and shall determine the cause of death and pass orders as deemed necessary.
- g. In case of clinical trial related death, the Licensing Authority, after considering there commendations of the Expert Committee, shall decide the quantum of compensation to be paid by the Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conducting the clinical trial and shall pass orders as deemed necessary within three months of receiving the report of the serious adverse event.

### **Cases of serious adverse events, other than deaths, shall be examined as given below:**

- a. The Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conducting the clinical trial and the Investigator shall forward their reports on serious adverse event, after due analysis, to the Licensing Authority as defined under rule 21(b), Chairman of the Ethics

#### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

## *Chapter 10: Review Of Serious Adverse Event And Other Safety Reports*

Committee and Head of the Institution where the trial has been conducted within ten calendar days of occurrence of the serious adverse event.

- b. The Ethics Committee shall forward its report on the serious adverse event, after due analysis, along with its opinion regarding the financial compensation, if any, to be paid by the Sponsor or his Representative, whosoever had obtained permission from the Licensing Authority as defined under Rule 21(b) for conducting the clinical trial, to the Licensing Authority within 30 calendar days of occurrence of the serious adverse event.
- c. The Licensing Authority shall determine the cause of injury and pass order as deemed necessary. The Licensing Authority shall have the option to constitute an independent Expert Committee, wherever considered necessary, to examine such serious adverse events of injury, which will recommend to the Licensing Authority for arriving at the cause of the injury and also the quantum of compensation in case of clinical trial related injury, to be paid by the Sponsor or his representative whosoever had obtained permission from the Licensing Authority as defined under rule 21(b) for conducting the clinical trial.
- d. In case of clinical trial related injury, the Licensing Authority, shall decide quantum of compensation to be paid by the Sponsor or his representative whosoever had obtained permission from the Licensing Authority for conducting the clinical trial and shall pass orders as deemed necessary within three months of receiving the report of the serious adverse event.
- e. The Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conducting the clinical trial, shall pay the compensation in case of clinical trial related injury or death as per the order of the Licensing Authority as defined under rule 21 (b) within thirty days of the receipt of such order.

**Review of Suspected Unexpected Serious Adverse Reaction (SUSAR) / CIOMS**

- All other sites SAEs, SUSARs, CIOMS and any other safety information pertaining to the trial have to be notified to IEC as per the timelines given in the guidelines or upon within 7 days of receipt.
- Safety Reports will be acknowledged by the Member Secretary and copy will be retained in the IEC study file/binder.
- All the Safety Reports or updates will be circulated to the members during the meeting
- IEC may ask to provide additional information related to SUSARs as required.

**Annexures**

1. Data Elements For Reporting Serious Adverse Events Occurring In A Clinical Trial (Table 5 Of New Drug And Clinical Trial Rule)
2. Due Analysis report template
3. Compensation formula

**a) DATA ELEMENTS FOR REPORTING SERIOUS ADVERSE EVENTS OCCURRING IN A CLINICAL TRIAL (Table 5 of New Drug and Clinical Trial Rule)**

Data Elements for reporting serious adverse events occurring in a clinical trial

1. Patient Details

- Initials & other relevant identifier (hospital/OPD record number etc.):
- Gender:
- Age and/or date of birth:
- Weight:
- Height:

2. Suspected Drug(s)

- Generic name of the drug:
- Indication(s) for which suspect drug was prescribed or tested:
- Dosage form and strength:
- Daily dose and regimen (specify units - e.g., mg, ml, mg/kg):
- Route of administration:
- Starting date and time of day:
- Stopping date and time, or duration of treatment:

3. Other Treatment(s)

- Provide the same information for concomitant drugs (including non prescription /OTC drugs) and non-drug therapies, as for the suspected drug(s):

4. Details of Suspected Adverse Drug Reaction(s)

**Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

## *Chapter 10: Review Of Serious Adverse Event And Other Safety Reports*

- Full description of reaction(s) including body site and severity, as well as the criterion (or criteria) for regarding the report as serious. In addition to a description of the reported signs and symptoms, whenever possible, describe a specific diagnosis for the reaction:
- Start date (and time) of onset of reaction:
- Stop date (and time) or duration of reaction:
- Dechallenge and rechallenge information:
- Setting (e.g., hospital, out-patient clinic, home, nursing home):

### 5. Outcome

- Information on recovery and any sequelae; results of specific tests and/or treatment that may have been conducted:
- For a fatal outcome, cause of death and a comment on its possible relationship to the suspected reaction; any post-mortem findings:
- Other information: anything relevant to facilitate assessment of the case, such as medical history including allergy, drug or alcohol abuse; family history; findings from special investigations etc:

### 6. Details about the Investigator

- Name:
- Address:
- Telephone number:
- Email ID:
- Profession (Speciality):
- Site ID:

*Chapter 10: Review Of Serious Adverse Event And Other Safety Reports*

- Date of reporting the event to Licensing Authority:
- Date of reporting the event to Ethics Committee overseeing the site:
- Signature of the Investigator:

7. Details about the Ethics Committee

- Name & Address
  - Name of Chairman & Address
  - Telephone/Mobile Number
  - Email

8. Causality Assessment by Investigator with reasoning for Relatedness/Un-relatedness along with supporting investigational documents.

9. Socioeconomic background of subject/patient viz. Qualification, Occupation, Monthly income

**b. Due Analysis report template**

**Due Analysis Report**

Study Title	
CTRI Registration No	
Study ID	
CRO Address	

Type of Report	
Type of SAE	
DCGI Acknowledgement details of Initial Report	

1. Patient Details

Initials	
Subject No	
Date of Birth/Age	
Gender	
Weight	
Height	
Hospital OPD Record No	

2. Suspected Drug(s)

Generic name of the drug	
Indication(s) for which suspect drug was prescribed or tested	
Dosage for and strength	
Daily dose and regimen	
Route of administration	
Starting date and time of day	
Stopping date and time, or duration of treatment	

3. Other Treatment(s)

Drug (Generic Name)	Dose/Route/Frequency	Start date	Stop date	Indication



4. Details of Suspected Adverse Drug Reaction(s)

Event	
Start date	
Stop date	
Relationship to study drug	
Outcome	
Severity	
De challenging/ Re challenging	
Setting	

Description of the event/s
----------------------------

5. Outcome

--

6. Laboratory Reports:

7. Action Taken for the Serious Adverse Event:

Chapter 10: Review Of Serious Adverse Event And Other Safety Reports

--

8. Details of Compensation:

--

9. Relatedness to Study Agent/ Study related procedure(s):

Investigator Causality	
------------------------	--

10. Details about the Investigator & Ethics Committee

Details about the Investigator	
Site ID	
Investigator Name	
Specialty	
Address	
Telephone No:	
Email ID	
Details about the Ethics Committee	
Name & Address	
Name of the Chairman & Address	
Telephone/ Mobile Number	

*Chapter 11 : Self Assessment Process*

Email	
-------	--

Date if reporting the event to Licensing Authority	
Date of reporting the event to the Ethics Committee overseeing the site	
Sponsor (Address with contact no and Email)	
Investigator's signature & date	

**INSTITUTIONAL ETHICS COMMITTEE**

**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**

**PUSHPAGIRI RESEARCH CENTRE,**

Thiruvalla, Kerala-689101, India

Ph: **0469 2775518**

**STANDARD OPERATING PROCEDURES**

**CHAPTER 11**

**SELF ASSESSMENT PROCESS**

## **CHAPTER 11**

### **SELF ASSESSMENT PROCESS**

#### **1.0 Purpose**

Purpose of this SOP chapter is to provide guidance for assessment of functioning of IEC.

#### **2.0 Scope**

This SOP Chapter applies the measures taken by IEC for the effective functioning.

#### **3.0 Responsibility**

The responsibility of self-evaluation of IEC functions shall lie with Chairperson and Member Secretary.

#### **Process**

IEC shall have a self-assessment system to ensure the effective functioning of IEC. Self-assessment shall be performed for each member. The self-evaluation shall be done annually. An Audit Committee shall be selected during the meeting which shall be approved by Chairperson.

One or more audit committees can be designated based on the requirement. All committees shall be approved in the full quorum meeting. The Audit Committee can be revised annually.

The Audit Committee shall be responsible for the assessment of functions and operations of IEC. The following areas shall be assessed by the Audit Committee once in a year.

- Functioning of IEC
- Attendance and Participation of Members
- Training and Certifications of Members
- Record Keeping and Archival
- Income and Expenditure of IEC
- Periodic Monitoring and Review
- SAE Management Process
- Documentation Management

#### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla

Version : 1.0 Dated:20<sup>th</sup> Nov 2019

## *Chapter 11 : Self Assessment Process*

- Administrative Support
- Performance of Members

The Audit Committee shall share the report to Member Secretary. The Member Secretary shall share the report to the Chairman and Head of Institution. The audit report shall be discussed in the full quorum IEC meeting and Corrective Action and Preventive Actions (CAPA) will be prepared and implemented by the Audit Committee. The implementation of CAPA shall be verified by Member Secretary and the same shall be discussed in the next EC meeting.

### **Assessment of EC Members**

IEC will do assessment of its functioning annually. The member secretary and Chairperson will do the self-assessment using the assessment form. Member Secretary will perform assessment the members and report to the Chairperson. Actions will be taken based on the assessment. The members may be retrained or removed based on the nonperformance in the EC functions.

### **Annexure**

1. Audit Checklist
2. Assessment form for members

**1.Audit Checklist**

	Name of the Assessor:	
	Period of Assessment:	
SI No	Assessment	Comments
1	No of meetings conducted	
2	Are IEC meetings held as per the timelines?	
3	Number of Protocols reviewed	
4	Number of Protocols approved	
5	Number of SAEs reported	
6	Number of SAEs reviewed	
7	Was SAE Management satisfactory	
8	Had effective compensation been paid to subjects	
9	Details of Trainings conducted by IEC	
10	Number of Monitoring's performed	
11	Number Complaints registered by subjects	
12	Details of action taken for the complaints	
13	Details of payment received and spent	
14	Details of reconstitution made in the IEC	
15	Were all the changes in the reconstitution reported to DCGI?	
16	Any revision in the SOP has been made	

2. Assessment form for members

**IEC Evaluation Form of Staff**

	Mention () the individual who is performing the evaluation:	Self – evaluation: <input type="checkbox"/> Member secretary IEC <input type="checkbox"/>
	Name of the person who is evaluated:	
	Role in IEC:	
SI No	Assessment	Comments
1	Handles workload efficiently	Yes: <input type="checkbox"/> No: <input type="checkbox"/>
2	Number of protocols processed that were reviewed	
3	Completion of required checklists and documentation	Yes: <input type="checkbox"/> No: <input type="checkbox"/>
4	Maintains paper files efficiently and correctly	Yes: <input type="checkbox"/> No: <input type="checkbox"/>
5	Prepares agenda and minutes in timely manner	Yes: <input type="checkbox"/> No: <input type="checkbox"/>
6	Maintain IEC rosters efficiently and correctly	Yes: <input type="checkbox"/> No: <input type="checkbox"/>
7	Prepare IEC records efficiently and correctly	Yes: <input type="checkbox"/> No: <input type="checkbox"/>
8	Completion of Training requirement	Yes: <input type="checkbox"/> No: <input type="checkbox"/>
9	Attendance at Training sessions	Regular: <input type="checkbox"/> Irregular: <input type="checkbox"/>
10	Number of Training sessions Attended	
11	Preparedness for meetings	Good: <input type="checkbox"/> Average: <input type="checkbox"/> Poor: <input type="checkbox"/>
12	Quality of pre-reviews	Good: <input type="checkbox"/> Average: <input type="checkbox"/> Poor: <input type="checkbox"/>
13	Communication with IEC chair	Good: <input type="checkbox"/> Average: <input type="checkbox"/> Poor: <input type="checkbox"/>



**INSTITUTIONAL ETHICS COMMITTEE**

**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**

**PUSHPAGIRI RESEARCH CENTRE,**

**Thiruvalla, Kerala-689101, India**

**Ph: 0469 2775518**

**STANDARD OPERATING PROCEDURES**

**CHAPTER 12**

**RECORD KEEPING AND ARCHIVAL**

## **CHAPTER 12**

### **RECORD KEEPING AND ARCHIVAL**

#### **1.0 Purpose**

Purpose of this SOP Chapter is to provide instructions for preparation and maintenance of active study files and other related documents approved by the IEC and storage/archival of closed study files and retrieval of documents.

#### **2.0 Scope**

This SOP chapter applies to all active protocol/study files, closed files and their related documents that are maintained in the IEC office and archival site

#### **3.0 Detailed Procedure**

All documentation and communication of an EC should be dated, filed, and archived with utmost confidentiality. The documents will be archived for a minimum period of 5 years following the completion of a study. The access is limited to the archived documents and tracked by a Register book for the entry and exit. EC Chairperson, Member Secretary and personnel delegated by Chairperson/Member Secretary only will have access to the archival area.

**Documents that should be filed and archived include, but are not limited to:**

##### **Administrative Documents**

- Constitution and composition of the EC
- Appointment letters
- Signed and dated copies of the most recent curriculum vitae of all EC members
- Signed confidentiality agreements
- COI declarations of members
- Training records of EC members
- Financial records of EC
- Registration/accreditation documents, as required

##### **Standard operating procedure**

Pushpagiri Institute of Medical Sciences,  
Pushpagiri Research Centre, Thiruvalla  
Version : 1.0 Dated:20<sup>th</sup> Nov 2019

- A copy of national and international guidelines and applicable regulations
- Regulatory notifications
- Meeting-related documents
- Agenda and minutes
- All communications received or made by the EC
- SOPs

### **Study-related documents**

- One hard copy and a soft copy of the initial research proposal and all related documents
  - Decision letters
  - Any amendments submitted for review and approval
  - Regulatory approvals
  - SAE, AE reports
  - Protocol deviations/violations
  - Progress reports, continuing review activities, site monitoring reports
  - All correspondence between the EC and researchers
  - Record of notification issued for premature termination of a study with a summary of the reasons
  - Final report of the study
  - Publications, if any
- Records can be maintained in hard copies as well as soft copies.
  - For each project a separate file will be maintained.
  - All the research related documents and communications of IEC will be dated and filed in the respective binders.
  - All the Study related documents will be filed in the respective study specific binders.
  - Documents related to regulatory clinical trials must be archived for 5 years after the completion/termination of the study or as per regulations.
  - The archival room will be provided with fire extinguisher and pest control to make sure the long term safety of the documents

### **Retrieval Procedure**

- The documents can be retrieved by Authorized personals by requesting via document request form to EC Member Secretary. Up on Permission copy of the requested documents will be shared which will be documented.
- If the investigator needs copy of the document. Investigator has to give document request form and the EC secretariat will issue the document within one week
- All the records shall be accessible for inspection and copying by authorized representatives of the regulatory at reasonable times and in a reasonable manner.

### **Final Disposal of documents**

The files will be disposed off by the IEC secretariat after the archival period of 5 years. A formal document tracking register will be maintained, providing details of the documents being written off / disposed off after notification to IEC in IEC meeting. The disposal shall be performed by means of shredding.

### **ANNEXURE**

1. Document Tracking register
2. Document request form

**1. Document Tracking register**

Proj ect No.	Title of Proj ect	IEC Appro val Date	No of Fil es	Study Initiati on date	Locati on of the storag e	Stud y Clos ure Date	Locati on of the storag e	Name of the authori zed individ ual archive d	Date of Destruct ion	Sign of the responsi ble person

**2. Document Request Form**

Name of Document requested:	Date:
Requested by:-	Study Title:-
<input type="checkbox"/> Principal investigator <input type="checkbox"/> IEC/IRB Member <input type="checkbox"/> Authority <input type="checkbox"/> Others.....	
Purpose of the request:	
Retrieved by:	Date:
Returned by:	Date:
Archived by:	Date:
Approved by:	Date:

**INSTITUTIONAL ETHICS COMMITTEE**  
**PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES,**  
**PUSHPAGIRI RESEARCH CENTRE,**  
**Thiruvalla, Kerala-689101, India**  
**Ph: 0469 2775518**

**STANDARD OPERATING PROCEDURES**

**Chapter 13**

**PREPARING FOR ETHICS COMMITTEE**  
**AUDIT/INSPECTION**

## **CHAPTER 13**

### **PREPARING FOR ETHICS COMMITTEE AUDIT/INSPECTION**

#### **1.0 Purpose**

The purpose of this Chapter is to guide an Institutional Ethics Committee (IEC) to prepare for an audit or inspection of the IEC.

#### **2.0 Scope**

This chapter applies to all the IEC members and the Secretariat.

#### **3.1 Responsibility**

It is the responsibility of the Member Secretary, Chairperson, IEC Members and the IEC Secretariat to keep IEC documents ready for audit and to be available to answer questions during audit or inspection by administrative and regulatory authorities.

#### **Detailed instructions**

As per the provision of rule 122DD of Drugs And Cosmetic Rule 1945, "The Ethics Committee shall allow inspectors of officials authorized by the Central Drugs Standard Control Organization to enter its premises to inspect any record, data or any document related to clinical trial and provide adequate replies to any query raised by such inspectors or officials, as the case may be, in relation to the conduct of the trial. This SOP chapter is also applicable for the preparation of any audit or inspection from external regulatory bodies.

#### **Receipt of notification of an Audit / Inspection**

On receipt of written/ mailed communication regarding audit/ inspection visit, the Member Secretary will inform the Chairperson, IEC members and the Head of Institution, if applicable about the date and purpose of the audit/inspection.

### **Preparing for the audit**

- On receiving information about the audit /inspection, IEC Member Secretary and/ or IEC member/s are given the responsibility by the Chairperson to prepare for the visit with assistance of the Secretariat.
- The Member Secretary and / or designated IEC member/s will make arrangements in accordance with the steps mentioned in the checklist
- The studies with incomplete / missing documents will be dealt with separately and actions taken will be documented.
- Care should be taken to ensure that all documents are kept in the right order for easy and quick access.

### **On the day/s of Visit**

- Chairperson / Member Secretary / designated IEC Member/s should welcome and accompany the auditors/inspectors to the reserved meeting room.
- Designated team members must be present in the meeting room.
- The conversation would start with the auditor/inspector stating the purpose of the visit and the type of information is needed.
- The IEC Chairperson / Member Secretary / IEC Members must answer questions of the auditors/inspectors clearly, politely, truthfully and straight to the point.
- The information and files requested by the auditors/inspectors should be made available by the Secretariat.
- The Member Secretary/ designated IEC member/ Secretariat will make note of the comments, recommendation of the auditors/inspectors.

### **Correction of deficiencies observed at audit/ inspection**

- Member Secretary/ designated IEC member/ Secretariat will review comments and recommendations of the auditor/inspector.



### *Chapter 13 : Preparing for Ethics Committee Audit/Inspection*

- On receipt of Audit/ Inspection Report the Chairperson should implement corrective and preventive measures and set the timeline for implementation of corrections as stated by the auditor/inspector.
- Action plan should be communicated by the Member Secretary/ designated IEC member to the auditor/inspector after seeking approval of the Chairperson.
- A review date for an internal follow-up audit will be decided by the Chairperson (if applicable).

The Member Secretary/ designated IEC member should report the outcome of the internal follow-up audit to the Chairperson.

#### **Recording the Audit/Inspection Visit**

- The Member Secretary/ designated IEC member/ Secretariat must keep record of the audit/inspection visit reports and action plans in a separate audit/inspection file.
- The completed checklist and findings from the internal follow-up audit (if applicable) must also be maintained in the internal audit file.\

#### **ANNEXURE**

##### 1. Check list

**ANNEXURE**

- Check list

SI.No	Activity	Yes / NO
1.	Date of letter of communication regarding audit/inspection:	
2.	Date(s) on which the audit/inspection has been agreed on:	
3.	To ensure the IEC members and staff have been informed about the date/s and time.	
4	To ensure availability of IEC related information – mandate, terms of reference, organization chart (in the print form) in the IEC office.	
5	To make sure of availability of latest copy /copies of signed SOPs in print form in the office and/ or in electronic form on the IEC computer/s.	
6	To review the SOPs and note details of any omissions or deviations, with reasons.	
7	To ascertain availability of all national and international ethics guidelines and regulations in print form and / or in electronic form in the IEC office.	
8	<p>To check the files of ongoing and complete research study files for the presence of all signed documents as stated below and to note any missing/ incomplete documentation and actions taken.</p> <ul style="list-style-type: none"> <li>➤ Records regarding applications of research studies for review including protocols and related documents</li> <li>➤ Protocol Assessment Records – Comments of IEC members, Meeting Agenda, Minutes (documented in individual study file or separately in meeting records file)</li> <li>➤ Communication records with investigator (documented in</li> </ul>	

	<p>individual study file)</p> <ul style="list-style-type: none"> <li>➤ Amendment Approvals (documented in individual study file)</li> <li>➤ SAE reports and SAE related communications with investigator and regulators</li> <li>➤ Protocol deviation/violation/exception reports(documented in individual study file)</li> <li>➤ Continuing and final completion/termination reports</li> </ul>	
9	<p>(documented in individual study file)</p> <p>To ensure availability of documents regarding list of members, tenure, appointment details, CVs, baseline and periodic training of IEC members</p>	
10	<p>To ensure availability of documents regarding appointment, CVs and training of staff of secretariat.</p>	
11	<p>To ensure measures for maintaining security of electronic database and office records.</p>	
12	<p>To make sure that maintenance, retrieval, storage, archival and tracking of the study files are done as per the respective SOPs.</p>	
13	<p>To ascertain proper labelling and indexing of study files and storage cabinets.</p>	
14	<p>To decide which members will communicate with auditors/ inspectors, be available for audit/inspection, prepare action plan and conduct follow-up audit(if applicable)</p>	
15	<p>To report about findings and report received regarding audit/inspection to IEC members at the full board IEC meeting.</p>	

**Minutes of the IRB committee on: 16<sup>th</sup> August, 2022**

Due to the prevailing Covid -19 pandemic situation, the IRB meeting was scheduled on an online platform (Google Meet) on **16<sup>th</sup> August, 2022**. The IRB Members and the Principal investigators were given the Google link before hand and were requested to join at 10:00 on **16<sup>th</sup> August, 2022**. The IRB Chairman welcomed Dr. Melvin, Associate Professor, SRM Medical College Hospital and Research Centre.

The previous minutes of the IRB Meeting was approved in this meeting.

**ATTENDANCE:** the table below lists all members of the ethics committee, their role, and attendance

Dr Harikumar B Nair	Ayurvedic Physician & Researcher	Chairperson
Dr Nebu George Thomas	Professor, Pushpagiri College Of Dental Sciences	Member Secretary
Dr Nibu Verghese	PhD (Plant Biotechnology)	Scientific Member
Dr Vikram Gowda	Vice-principal, Medical college	Medical Scientist
Dr Liya Roslin Joseph	Assistant Professor of Pharmacology	Medical Scientist
Fr. Sibin Mathew	Bachelor in Theology	Member
Dr T M Chary	PhD	Scientific Member
Mr Lijo George	B.Com	Lay Person
Adv. Minu Mathews	Advocate	Legal Expert
Dr. T P Thankappan	MBBS (MD-Dermatology and Venereology)	Clinician
Dr. G. Sulochana	MBBS, MD-Pathology	Basic Medical Scientist
Dr Athulya G Asokan	MD (General Medicine)	Member
Dr Tressia Alias Princy Paulose	PhD Chemistry	Member
Dr. Stephen James	M Tech	Member
Dr. Melvin	Associate Professor from SRM Medical College Hospital and Research Centre.	External Subject Expert

**Members Absent with apologies:** 3

**Non-Voting Member:** NIL

**Members alternating:** NIL

**Guests (Include Affiliation):** Dr. Melvin, Associate Professor, SRM Medical College Hospital and Research Centre.

**Total count:** 12 out of 15.

**Quorum:** The quorum was present. > 50% members with 5 specified category as per ICMR Guidelines/Schedule Y. The chair person called the meeting to order, after confirming the Quorum was present

**Attendance Notes:**

- Members in attendance who recused themselves: None
- Conflict of Interest of IRB Members: None

Regulations followed for IRB Motion: Schedule Y, ICMR 13 principles

## **I: INITIALREVIEW**

**IRB Study Reference No: 01/2022**

**Protocol Title:** A pilot study of the use and perceived utility of ECDT to assess clinical dental teaching within an Indian Dental college setting.

**Principal Investigator: Dr. Subbalekshmi**

**Primary reviewer of IRB: Comments from IRB Member**

**Dr. Athulya**

1. How are you going to fulfil the second and third objective?
2. Will you be giving separate questionnaire for each subject?

**Dr. Nebu**

1. What is the duration of the study?
2. What is the sample size?
3. Did you follow a sample size formula to calculate sample size?
4. It would be better to do a multicentric study to avoid bias.

**Motion:**

**Comments:**

**IRB Study Reference No: 02/2022**

**Protocol Title:** Comparative study on the effect of citicoline versus calcium in osteoporosis.

**Principal Investigator: Dr. P S John**

**Primary reviewer of IRB: Comments from IRB Member**

**Dr. Athulya**

1. What is the difference between group I and group II?
2. Where are you planning to do DEXA scan?
3. Any exclusion criteria for patients?
4. Do you expect any adverse effects in patients?
5. Will you be have a separate adverse effect reporting?

**Dr. Melvin**

1. Are you using bisphosphonate for treatment?
2. As group II patients are only receiving citicholine, are you denying them from proper treatment?

**Motion:**

**Comments:**

**IRB Study Reference No: 03/2022**

**Protocol Title:** A comparative study on the effect of citicoline versus calcium in non-union of fractures.

**Principal Investigator: Dr. P S John**

**Primary reviewer of IRB: Comments from IRB Member**

**Dr. Melvin**

1. Is this a heterogeneous group of study?
2. How will you manage the analysis?
3. Can you restrict your study to one particular area of fracture
4. What is your sample size?
5. If your not receiving your sample size, it would be better if you make it a multicentric study

**Dr. Athulya**

1. Can you define non- union of fracture mentioned in your inclusion criteria
2. It would be better if you can analyse the reasons of non-union of fractures

**Motion:**

**Comments:**



**IRB Study Reference No: 04/2022**

**Protocol Title:** A comparative study on acceleration of fracture healing in osteoporotic fractures with citicoline versus calcium.

**Principal Investigator: Dr. P S John**

**Primary reviewer of IRB: Comments from IRB Member**

**Dr. Melvin**

1. Record the safety of the subject and submit the report to IRB
2. Suggesting a multicentric study for getting a good sample size

**Motion:**

**Comments:**

**IRB Study Reference No: 05/2022**

**Protocol Title:** Deep Learning Approach for the Diagnosis of Pediatric Heart Disease using Wireless Phonocardiogram

**Principal Investigator: Dr. Saji Philip**

**Primary reviewer of IRB: Comments from IRB Member**

**Dr. Melvin**

1. Where is the study been done?
2. Can you get the information from data base
3. What is the sample size?
4. Will the selected sample size be sufficient for deep learning?
5. Is there any work published in India?
6. Have you made a device for this study?
7. Who is doing validation of the study?

**Dr. Athulya**

1. Will you confirm the study with echocardiography?
2. Will all patients undergo echocardiography?
3. How are you going to divide the sample?

**Motion:**

**Comments:**

**IRB Study Reference No: 06/2022**

**Protocol Title:** A study on Clinical Profile of ESUS and Cardioembolic study upon South Indian patients

**Principal Investigator:** Dr. Nikhil

**Primary reviewer of IRB:** Comments from IRB Member

**Dr. Melvin**

1. How investigator going to analyse the health related quality of life ?

**Motion:**

**Comments:**

**IRB Study Reference No: 07/2022**

**Protocol Title:** The Role of community in tackling antibiotic resistance in India: A Cross-sectional study

**Principal Investigator:** Dr. Philip Mathew

**Primary reviewer of IRB:** Comments from IRB Member

**Dr. Melvin**

1. Where is the centre of the study?
2. Once you get approval, submit the investigators list and centre of study.
3. Who is the coordinator for this study?

**Motion:**

**Comments:**

**IRB Study Reference No: 08/2022**

**Protocol Title:** Assessment of the multi-sectoral impact of the National Action Plans on Antimicrobial Resistance in Bangladesh and Vietnam: A qualitative study

**Principal Investigator: Dr. Philip Mathew**

**Primary reviewer of IRB: Comments from IRB Member**

**Dr. Melvin**

1. Who are the people participating in the study?
2. Will this IRB approval be enough to conduct study in Bangladesh and Vietnam
3. Is there any MOU signed with these institutions?
4. It is better to have agreement signed among the investigator level and submit to Ethics committee of Pushpagiri

**Motion:**

**Comments:**

**IRB Study Reference No: 09/2022**

**Protocol Title:** Enablers and barriers for state action plans for antimicrobial resistance in India:  
A multicentric study

**Principal Investigator: Dr. Philip Mathew**

**Primary reviewer of IRB: Comments from IRB Member**

**Dr. Melvin**

1. It is better to have agreement signed among the investigator level and submit to Ethics committee of Pushpagiri

**Motion:**

**Comments:**

**IRB Study Reference No: 10/2022**

**Protocol Title:** EEG monitoring Findings in critically Ill adults with impaired consciousness and their correlation with clinical and functional outcome

**Principal Investigator: Dr. Miny Susan Abraham**

**Primary reviewer of IRB: Comments from IRB Member**

**Dr. Melvin**

1. Are you taking data from records?
2. Is this a retrospective study?
3. Will you have sufficient data to record?

**Dr Athulya**

1. Are you going to follow-up all patients after 1 month?
2. If you lose patients, how will you adjust the sample size?
3. Kindly modify your objective – pattern instead of prevalence
4. Modify your third objective

**Motion:**

**Comments:**

**IRB Study Reference No: 11/2022**

**Protocol Title:** Longitudinal effects of non-restorative caries control treatment on Oral Health related quality of life, salivary microbial levels and immunoglobulin levels in children with Autism Spectrum Disorder

**Principal Investigator: Dr. Sherin Sara George**  
**Primary reviewer of IRB: Comments from IRB Member**

**No Comments**

**Motion:**  
**Comments:**

**IRB Study Reference No: 12/2022**

**Protocol Title:**

Low heme iron intake as a predictor of iron deficiency in adolescent girls

**Principal Investigator: Dr. Asha K K**  
**Primary reviewer of IRB: Comments from IRB Member**

**Dr. Melvin**

1. You should get a document from CIFT (parent institution) regarding the reference of above study of Pushpagiri institutional ethics committee (IEC).
2. ICMR letter giving permission of IEC to review the above study

**Motion:**  
**Comments:**

**IRB Study Reference No: 13/2022**

**Protocol Title:** Use of OLFM4 as prognostic marker in Type 2 diabetes and its role in S.aureus survival in neutrophils

**Principal Investigator: Dr. Haritha V H**

**Primary reviewer of IRB: Comments from IRB Member**

**Dr. Melvin**

1. Does your study include blood sample collection?

**Motion:**

**Comments:**

**IRB Study Reference No: 14/2022**

**Protocol Title:** Perception of Indian medical and dental practitioners regarding the 2022 outbreak of monkey pox disease

**Principal Investigator: Dr. Nebu George Thomas**


**Primary reviewer of IRB: Comments from IRB Member**

**No Comments**

**Motion:**

**Comments:**

Dr. Aby Mathew T. MDS  
Principal  
Pushpagiri College of Dental Sciences





**INSTITUTIONAL REVIEW BOARD  
PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES & RESEARCH CENTRE**

No: IRB/01/2023

21st January, 2023

**Minutes of the IRB committee**

1. Due to the prevailing Covid -19 pandemic, the IRB meeting was scheduled online (Google Meet) on **12<sup>th</sup> January, 2023**. The IRB Members and the Principal investigators were given the meet link before hand and were requested to join at 09 am on **12<sup>th</sup> January, 2023**. The IRB Chairman welcomed Dr. Melvin Associate Professor from SRM Medical College Hospital and Research Centre.
2. The previous minutes of the IRB Meeting was approved in this meeting.

**ATTENDANCE:** the table below lists all members of the ethics committee, their role, and attendance

Dr Harikumar B Nair	Ayurvedic Physician & Researcher	Chairperson
Dr Nebu George Thomas	Professor, Pushpagiri College Of Dental Sciences	Member Secretary
Dr Vikram Gowda	Vice-principal, Medical college	Medical Scientist
Dr Liya Roslin Joseph	Assistant Professor of Pharmacology	Medical Scientist
Fr. Sibin Mathew	Bachelor in Theology	Member
Dr T M Chary	PhD	Scientific Member
Mr Lijo George	B.Com	Lay Person
Adv. Minu Mathews	Advocate	Legal Expert
Dr Athulya G Asokan	MD (General Medicine)	External Member
Dr Tressia Alias Princy Paulose	PhD Chemistry	Member
Dr. Stephen James	M Tech	Member
Dr. Melvin	Associate Professor from SRM Medical College Hospital and Research Centre.	External Subject Expert

**Members Absent with apologies:** NIL

**Non-Voting Member:** NIL

**Members alternating:** NIL

**Guests (Include Affiliation):** Dr. Melvin, Associate Professor from SRM Medical College Hospital and Research Centre.

**Total count:** 12 out of 12.

**Quorum:** The quorum was present. > 50% members with 5 specified category as per ICMR Guidelines/Schedule Y. The chair person called the meeting to order, after confirming the Quorum was present

**Attendance Notes:**

- Members in attendance who recused themselves: None
- Conflict of Interest of IRB Members: None

Regulations followed for IRB Motion: Schedule Y, ICMR 13 principles

Study Number	TITLE OF THE PROPOSAL	NAME OF PI
01/ 2023	<p><b>Prevalence of temporomandibular disorders and its association with text neck syndrome due to Smartphone use among undergraduate dental students in kerala – a cross sectional study.</b></p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Will you be able to get enough samples in group II (Second image) shown in your presentation? If not changing the group would be better to maintain an adequate sample size.</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	Dr. Aby Mathew T
02/2023	<p><b>Knowledge and Attitude about Obstructive Sleep Apnoea among dental students in Kerala, India</b></p> <p><b>Motion:</b> <b>Comments:</b></p> <p>No Comments</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	Dr. Ivin Elsa John

<p><b>03/2023</b></p>	<p><b>Breaking bad news: Communication skill of dentists</b></p> <p><b>Motion:</b> <b>Comments:</b></p> <p>As your PI is from abroad, is he supporting your study or are you including dentists from there also? Will you be providing the questionnaire online?</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Sunu Alice Cherian</b></p>
<p><b>04/2023</b></p>	<p><b>Comparative study on the effect of citicoline Supplementation in the treatment of AVN (avascular necrosis) of femoral head.</b></p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Will you get the adequate sample size? Can you consider a multicentric study?</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. P S John</b></p>
<p><b>05/2023</b></p>	<p><b>Comparitive study on the effect of citicoline versus Calcium in aseptic loosening of total hip arthroplasty.</b></p> <p><b>Motion:</b> <b>Comments: Nil</b></p>	<p><b>Dr. P S John</b></p>

	<p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
06/2023	<p><b>Identification of multimorbidity clusters and statistical modelling of associated risk factors among older adults of Kerala</b></p> <p><b>Motion:</b> <b>Comments:</b></p> <ol style="list-style-type: none"> <li>1. What is the sample size of your study?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Nisha Kurian</b></p>
07/2023	<p>Anatomical study on Retrohepatic segment of Inferior vena cava and variation in the pattern of hepatic vein ostia in South Kerala population</p> <p><b>Motion:</b> <b>Comments:</b></p> <ol style="list-style-type: none"> <li>1. Are these not prescribed earlier</li> <li>2. What is the implication of this study</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Stelin Agnes Michael</b></p>
08/2023	<p>Gross anatomical study of variations of Human liver in South Kerala population</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Nil</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Stelin Agnes Michael</b></p>

<p><b>09/2023</b></p>	<p>Opinions and Experiences about patients online access to their full health records – A mixed method study among the stake holders in Kerala</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Nil</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Gaddam Vijaya Lakshmi</b></p>
<p><b>10/2023</b></p>	<p><b>Cost effectiveness analysis of Unfractionated Heparin and Low molecular weight heparin: Enoxaparin among patients with acute myocardial infarction in a tertiary care hospital</b></p> <p><b>Motion:</b> <b>Comments: Nil</b></p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Liya Roslin Joseph</b></p>
<p><b>11/2023</b></p>	<p><b>Comparison of pregnancy outcome and medical complications in elderly primigravida with that of younger primigravida.</b></p> <p><b>Motion:</b> <b>Comments:</b></p> <ol style="list-style-type: none"> <li>1. Is this an observational study</li> <li>2. What is the novelty of the study</li> <li>3. How are you going to follow-up the patients upto delivery</li> </ol>	<p><b>Dr. Fathimma Ali</b></p>

	<p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
12/2023	<p><b>Evaluation of bacteriophages as biotherapeutic agents for chronic wound infections</b></p> <p><b>Motion:</b> <b>Comments:</b></p> <ol style="list-style-type: none"> <li>1. What is the hypotheis of the study?</li> <li>2. What is the novelty in this study?</li> <li>3. Will you be getting approval from the animal ethics committee?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Yogesh Bharat Dalvi</b></p>
13/2023	<p><b>Study of microbiomes of implanted urinary catheter and development of Catheter biopolymer with reduced biofilm formation</b></p> <p><b>Motion:</b> <b>Comments:</b></p> <ol style="list-style-type: none"> <li>1. What is the source of funding?</li> <li>2. Based on past experiences what is the percentage of catheter biofilm?</li> <li>3. Will you be considering only samples with catheter biofilm?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Reena Thomas</b></p>
14/2023	<p><b>Personality profile of patients with alcohol use disorder attending deaddiction clinic of a tertiary care centre in southern India</b></p> <p><b>Motion:</b></p>	<p><b>Dr. Vijayalal Vijayan</b></p>


	<p><b>Comments:</b></p> <ol style="list-style-type: none"> <li>1. How many types of personality disorders are you expecting to get?</li> <li>2. Will the sample size be enough to do group analysis</li> <li>3. Are you trying to state that people with personality disorders are more prone to alcohol dependence or vice versa.</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
15/2023	<p><b>Assessment of pattern of eating behaviour and its association with Non Alcoholic Fatty Liver Disease.</b></p> <p><b>Motion: Comments:</b></p> <ol style="list-style-type: none"> <li>1. What is your objective of the study?</li> <li>2. How will you screen your control patients?</li> <li>3. When will you interview your patients?</li> <li>4. Are you including only new cases of fatty liver?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Punya Chandran.</b></p>
16/2023	<p><b>Maternal and fetal outcome in pregnant women with threatened Miscarriage</b></p> <p><b>Motion: Comments:</b></p> <ol style="list-style-type: none"> <li>1. As there are many published studies done in Kerala, what is the novelty of this study?</li> </ol>	<p><b>Dr. Riya Mary Saju</b></p>



	<p>2. What is the justification for carrying out this study?</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
17/2023	<p><b>Correlation between risk factors of cardiovascular diseases and carotid intima media thickness (CIMT) in chronic kidney disease patients admitted in tertiary care centre in Kerala.</b></p> <p><b>Motion:</b> <b>Comments:</b></p> <p>1. What is the novelty in this study?</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<b>Dr. Chandana Ram</b>
18/2023	<p><b>Variations in origin and branching pattern of Coeliac Trunk and Superior Mesenteric Artery among patients undergoing abdominal imaging in a Tertiary Care Centre in South Kerala</b></p> <p><b>Motion:</b> <b>Comments:</b></p> <p>1. Is this a retrospective study? 2. Will you be able to trace the course of the artery in the specimen? 3. Do you need special tools for this?</p>	<b>Dr. Gaddam Vijaya Lakshmi</b>

	<p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
--	---	--

Dr. Aby Mathew T. MDS  
Principal  
Pushpagiri College of Dental Sciences



**INSTITUTIONAL REVIEW BOARD  
PUSHPAGIRI INSTITUTE OF MEDICAL SCIENCES & RESEARCH CENTRE**

No: IRB/02/2023

6<sup>th</sup> May, 2023

**Minutes of the IRB committee**

1. Due to the prevailing Covid -19 pandemic, the IRB meeting was scheduled online (Google Meet) on **25<sup>th</sup> April, 2023**. The IRB Members and the Principal investigators were given the meet link before hand and were requested to join at 09 am on **25<sup>th</sup> April, 2023**. The IRB Chairman welcomed Dr. Arun M Xavier, Amrita School of Dentistry.
2. The previous minutes of the IRB Meeting was approved in this meeting.

**ATTENDANCE:** the table below lists all members of the ethics committee, their role, and attendance

Dr Harikumar B Nair	Ayurvedic Physician & Researcher	Chairperson
Dr Nebu George Thomas	Professor, Pushpagiri College Of Dental Sciences	Member Secretary
Dr Vikram Gowda	Vice-principal, Medical college	Medical Scientist
Dr Liya Roslin Joseph	Assistant Professor of Pharmacology	Medical Scientist
Fr. Sibin Mathew	Bachelor in Theology	Member
Dr T M Chary	PhD	Scientific Member
Mr Lijo George	B.Com	Lay Person
Adv. Minu Mathews	Advocate	Legal Expert
Dr Athulya G Asokan	MD (General Medicine)	External Member
Dr Tressia Alias Princy Paulose	PhD Chemistry	Member
Dr. Stephen James	M Tech	Member
Dr. Rosin George Varghese	Assistant Professor, Department of Community Medicine	Internal Member
Dr. Arun M Xavier	Amrita School of Dentistry	External Subject Expert

**Members Absent with apologies:** NIL

**Non-Voting Member:** NIL

**Members alternating:** NIL

**Guests (Include Affiliation):** Dr. Arun M Xavier, Associate Professor, Amrita School of Dentistry

**Total count:** 13 out of 13.

**Quorum:** The quorum was present. > 50% members with 5 specified category as per ICMR Guidelines/Schedule Y. The chair person called the meeting to order, after confirming the Quorum was present

**Attendance Notes:**

- Members in attendance who recused themselves: None
- Conflict of Interest of IRB Members: None

Regulations followed for IRB Motion: Schedule Y, ICMR 13 principles

SL NO	TITLE OF THE PROPOSAL	NAME OF PI
<ul style="list-style-type: none"> <li>General Discussion: Previous Meeting Minutes Approval Welcoming of Dr. <b>Arun M Xavier, Amrita School of Dentistry</b></li> </ul>		
<p><b>01/2023</b></p>	<p>Role of Natriuretic Peptides and Inflammatory Markers levels in Hypercholesterolemia: A Case Control Study</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Liya</p> <ol style="list-style-type: none"> <li>1.Explain how you will select case and control in your study?</li> <li>2. How to overcome bias in selecting patients</li> <li>3. Does age have any role in your study?</li> <li>4. Are you going age and gender matching?</li> </ol> <p>Dr. Rosin</p> <ol style="list-style-type: none"> <li>5. What are the inclusion criteria for selecting the patients?</li> <li>6. Sample size calculation recalculate as per the objective stated.</li> <li>7. suggestion - Study setting centre can include general medicine area</li> </ol> <p>Dr. Athulya</p> <ol style="list-style-type: none"> <li>8.Better to include newly diagnosed patients with dyslipidemia than those on treatment.</li> <li>9. Study duration seems quite short for patient recruitment</li> <li>10. Is it a case control study??A prospective observational study would be a better term.</li> <li>11. Funding of the study and budget not clear</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Soumya R S</b></p>
<p><b>02/2023</b></p>	<p>Role of vitamin D in sleep quality of medical undergraduate students.</p> <p><b>Motion:</b> <b>Comments:</b></p>	<p><b>Dr. Amrutha Mary Zacharia</b></p>

Dr. Nebu

1. Students are considered as vulnerable population- there are chances of Bias in the study if you select students from you own institution
2. Better to do study in another institution

Dr. Liya

3. Since you are withdrawing blood, better to include this in the consent form
4. Students should not be charged for testing the blood
5. Consider the Confounders in your study and exclude them

Dr. Chary

6. Which form of Vitamin D are you analysing
7. Why not analysing 125 form of vitamin D
8. Title is confusing. Kindly reframe as correlation/ association

Dr. Rosin

9. What is the primary objective?
10. Include all data obtained which can be used for further analysis

Dr. Athulya

11. Kindly provide details on the funding of the study.
12. There can be many confounders for the study like using electronic devices close to bed time, meeting deadlines/ stress during exams, a sleeping environment that is noisy or not having the right temperature. Kindly modify the Performa so as to minimize confounders or modify the inclusion/exclusion criteria.

\*The PI will start the study only after the receipt of approval letter by the Committee.

<p><b>03/2023</b></p>	<p>Antidepressant Prescription Patterns and Clinical Correlates within Psychiatry Treatment Settings in Asia: A Cross Sectional REAP Consortium Study (REAP-AD3)</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Rosin</p> <ol style="list-style-type: none"> <li>1. What will be the criteria for selecting the patients?</li> <li>2. What is your sample size?</li> <li>3. How many centres have you selected for this study?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Roy Abraham Kallivayalil</b></p>
<p><b>04/2023</b></p>	<p>Central Venous Access Device Management in Critical Care Units – A Multicentric Implementation Project in Low Resource Setting</p> <p><b>Motion:</b> <b>Comments : Nil</b></p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Sunu Alice Cherian</b></p>
<p><b>05/2023</b></p>	<p>Penetration depth of irrigants into root dentine after Activation using manual dynamic activation, Navitip Fx, Sonic and Xp Endo finisher file – An in vitro study</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. Protocol is submitted in PDF format. Reformat it to the IRB protocol sample.</li> <li>2. Suggestion to include comparative study in the title</li> <li>3. Are you only including only manual methods?</li> </ol>	<p><b>Dr . Aswathi U</b></p>

	<ol style="list-style-type: none"> <li>4. What are the expected findings in your study?</li> <li>5. What studies are considered in sample size calculation?</li> <li>6. No citation was included in sample size calculation slide</li> <li>7. Its better to change Group O to control group</li> <li>8. Who will take and upload the images?</li> <li>9. What is the quantity of methylene blue used in your study?</li> <li>10. Who will assess the median penetration?</li> <li>11. What are the expected outcome?</li> </ol> <p>Dr Rosin</p> <ol style="list-style-type: none"> <li>1. What was the sample size that came out after calculating with the formula?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
<p><b>06/2023</b></p>	<p>Comparative evaluation of caries removal with smart bur and ceramic bur -an in vitro CBCT volumetric study</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. In the summary of the protocol cite references</li> <li>2. Cite your key article in the protocol</li> <li>3. Sample size calculation need clarity</li> <li>4. How are you going to standardise the teeth used for the study</li> <li>5. What are your inclusion and exclusion criteria?</li> <li>6. Mention how are you going to standardise the decay? Its always better to follow a criteria</li> <li>7. How will you measure the volume of caries removal?</li> <li>8. Include this in the protocol is separate software is used.</li> <li>9. Include the flow chart in the protocol.</li> </ol>	<p><b>Dr. T A Arif</b></p>



	<p>10. What is the difference between 2 types of burs?  11. The study outcome mentioned is not clear.  12. What is the dye used for detection of caries?  What quantity and time will dye be used?</p> <p>Dr. Rosin</p> <p>1. How will you divide the sample size and how will you select which bur to be used in which tooth?</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
<p><b>07/2023</b></p>	<p>Comparative Evaluation Of The Influence Of Temperature On The Cyclic Fatigue Of Reciproc Blue And Waveone Gold, Reciprocating Files – An Invitro Study</p> <p><b>Motion:</b>  <b>Comments:</b></p> <p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. In research problem and summary cite references.</li> <li>2. What is the difference between cyclic fatigue and cyclic fatigue resistance?</li> <li>3. Why did you chose temperature at 35 and 39 degree Celsius?</li> <li>4. How will you maintain the temperature?</li> <li>5. Does instrument has thermometer attached?</li> <li>6. In sample size calculation, cite references</li> <li>7. Why is sample size high?</li> <li>8. What was the results of the key article?</li> <li>9. Are you checking both groups at sample temperature?</li> <li>10. What is machine oil used in this study?</li> <li>11. Where are you doing the analysis?</li> <li>12. Who charted the budget for your study?</li> </ol>	<p><b>Dr. Ajanya K</b></p>

	<p>Dr. Rosin</p> <ol style="list-style-type: none"> <li>1. Are you using the same file system in you key article?</li> <li>2. Its better to find out a study that used same material as you have planned.</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
<p><b>08/2023</b></p>	<p>Comparative Analysis Of The Levels Of Tissue Inhibitors Of MMP In GCF Using Micro Osteoperforation Induced And Conventional Canine Retraction Technique</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. Why do we need to know the biological action in MOP?</li> <li>2. How do you expect change in current treatment modality?</li> <li>3. Cost of performing MOP</li> <li>4. In sample size add the key article.</li> <li>5. Will you be considering diet, oral hygiene while selecting the patients? How will you monitor this?</li> <li>6. How will you monitor the entire study?</li> <li>7. What are the exclusion criteria?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Drishya Padmanabhan</b></p>
<p><b>09/2023</b></p>	<p>A Comparative Analysis Of The Levels Of Runx2 In Gcf Using Micro-Osteoperforation Induced And Conventional Canine Retraction Techniques</p> <p><b>Motion:</b> <b>Comments:</b></p>	<p><b>Dr. Manjusha Baker</b></p>

	<p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. From where will you purchase the ELISA kit?</li> <li>2. How long will it take to reach you?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
10/2023	<p>In-Vitro Comparative Assessment Of Bone Regenerative Potential Of Fish Scale Derived Hydroxyapatite Loaded With Simvastatin And Fish Scale Derived Hydroxyapatite.</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. Suggestion to reframe the objectives</li> <li>2. Are there similar studies done in your department?</li> <li>3. What are the expected outcome?</li> <li>4. Are you checking for the biofunctionality of the graft?</li> </ol> <p>Dr. rosin</p> <ol style="list-style-type: none"> <li>1. What is the variable used for sample size calculation?</li> <li>2. Are you considering systolic blood pressure as mentioned in your protocol?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	Dr. Lekshmi M
11/2023	<p>Comparative Assessment Of Salivary Cystatin C Levels In Healthy And Severe Periodontitis Patients.</p> <p><b>Motion:</b> <b>Comments:</b></p>	Dr. Kavya S

	<p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. Why can't you have 2 groups – stage 3 and stage 4</li> <li>2. Better to stick on to a particular group either 3 or 4</li> <li>3. Is Cystatin already studied in literature?</li> <li>4. Is there any novelty in this study?</li> </ol> <p>Dr. Rosin</p> <p>Sample size has to be re calculated.</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
<p><b>12/2023</b></p>	<p>The Comparative Evaluation Of Biocompatibility In Synthetic And Fish Scale Derived Hydroxyapatite Coated Titanium Implant:-An Invitro Study.</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. Is there any study proving osseintegration in fish scales is better than synthetic hydroxyapatite?</li> <li>2. Are you checking for Osteopontic expression?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr Merin Basil</b></p>

<p><b>13/2023</b></p>	<p>Comparative Evaluation Of Flexural Strength And Surface Roughness Of Denture Base Resins Incorporated With Zirconium Oxide Nanoparticles And Thymoquinone - Antimicrobial Agents- An In-Vitro Study.</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr Arun</p> <ol style="list-style-type: none"> <li>1. What is the novelty in your study?</li> <li>2. What are the study centres?</li> <li>3. How will you consider the methodology by following any previous studies?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Riya Sabu</b></p>
<p><b>14/2023</b></p>	<p>Comparative Evaluation Of Static Compressive Strength And Fractography Analysis Between Conventional Titanium Implants And Alumina Toughened Zirconia Implants: An In-Vitro Study</p> <p><b>Motion:</b> <b>Comments:</b></p> <ol style="list-style-type: none"> <li>1. What are the disadvantage of Zirconia?</li> <li>2. Where are both tests being done?</li> <li>3. Why do you consider both conventional and customised implants?</li> <li>4. How are samples being considered?</li> <li>5. Modify the methodology and reframe it</li> <li>6. Table of analysis not in the protocol</li> </ol> <p>Dr.Rosin</p> <ol style="list-style-type: none"> <li>1. What is the sample size</li> <li>2. Recalculate the sample size</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Girish Harikumar</b></p>

<b>15/2023</b>	<p>Assessment Of Occlusal Derrangement Using T Scan In Patients Treated With Orif For Fracture Of Maxilla And Mandible –A Prospective Longitudinal Study</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. Can all variables be measured by T scan</li> <li>2. Exclusion criteria non TMJ patients have to be added in protocol</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<b>Dr. Shyam</b>
<b>16/2023</b>	<p>Comparative Evaluation Of Stability Of Single Titanium 4-Hole Miniplate, Two Titanium 4-Hole Miniplates And Single Titanium 4-Hole 3d Plate In Open Reduction And Internal Fixation Of Mandibular Angle Fractures: An In Vitro Study In Capra Aegagrus Malabaricus</p> <p><b>Motion:</b> <b>Comments:</b></p> <ol style="list-style-type: none"> <li>1. What is the difference between group 2 and 3?</li> <li>2. Are you following the standard protocol in you study?</li> <li>3. Why was the budget Rs 75,000/?</li> <li>4. How easy is it to collect goat mandible?</li> <li>5. References have to be cited.</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<b>Dr. Adithya Uday</b>

	LUNCH BREAK	
<b>17/2023</b>	<p>Comparative evaluation of changes in vertical dimension of occlusion and gingival crevicular fluid biomarker TNF<math>\alpha</math> following the placement of Stainless steel crowns by Hall technique and Conventional technique – A split mouth study</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. How was sample size calculated?</li> <li>2. Cite the references of the article.</li> <li>3. Add reference for each part of methodology</li> <li>4. Make sure the patients you chose have good level of oral hygiene and have got all decayed tooth restored.</li> </ol> <p>Dr. Rosin</p> <ol style="list-style-type: none"> <li>1. Sample size has to be recalculated</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<b>Dr. Namitha Jayan</b>
<b>18/2023</b>	<p>Comparative Evaluation Of The Remineralizing Effects Of Nanohydroxyapatite And Sodium Fluoride Containing Tooth Paste On Artificially Induced Dental Caries Of Human Enamel – An Invitro Study</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. Add reference regarding sample size calculation</li> <li>2. What is the primary and secondary outcome of this study?</li> <li>3. How will you take sample size from block/ embedded throughout the study</li> </ol>	<b>Dr. Jinimol</b>

	<p>4. Is methodology designed as per the key article?  5. How will you simulate oral environment?  6. As the protocol submitted was different from what was presented today, you will have to resubmit the proposals with all corrections.</p> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
<p><b>19/2023</b></p>	<p>Identifying DNA Methylation Based Biomarker(S) In The Progression Of Oral Squamous Cell Carcinoma: A Cross Sectional Study.</p> <p><b>Motion:</b>  <b>Comments:</b></p> <p>Dr. Arun</p> <ol style="list-style-type: none"> <li>1. Have you already selected the patients?</li> <li>2. Will you use a standardised questionnaire before selecting the patients?</li> <li>3. What are your inclusion criteria?</li> <li>4. Should your patients have any lesions?</li> <li>5. Till what stage of cancer will you select for your study?</li> <li>6. How will you check for methylation profile?</li> <li>7. What is the reason for choosing the markers?</li> <li>8. What are the study outcomes?</li> </ol> <p>Dr. Rosin</p> <ol style="list-style-type: none"> <li>1. Will you be looking for role of alcohol in your study?</li> <li>2. Better to include control in you study while assessing habit</li> <li>3. What are you planning to do with patients with habits?</li> <li>4. Will you take samples from 3 sites always for biopsy?</li> </ol>	<p><b>Dr. Sharlene Sara Babu</b></p>



	<p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	
20/2023	<p>Cardiometabolic Risk And Periodontal Disease</p> <p><b>Motion:</b> <b>Comments:</b></p> <p>Dr. Arun</p> <p>Why did you choose MMP-8?</p> <ol style="list-style-type: none"> <li>2. What are the clinical parameters checked in general medicine?</li> <li>3. What is the need of estimating MMP-8 from both blood and saliva?</li> <li>4. Name the co-investigators in this study.</li> <li>5. Are you expecting any outcome change as per specific geographic locations?</li> <li>6. As there is huge variation range in terms of age, will there be variation in the results. Its better to categorise as per the age group.</li> <li>7. Suggestion to remove the term convenient sampling.</li> </ol> <p>Dr. Rosin</p> <ol style="list-style-type: none"> <li>1. How did you select the sample size?</li> <li>2. What study design are you following?</li> </ol> <p>*The PI will start the study only after the receipt of approval letter by the Committee.</p>	<p><b>Dr. Julie Toby</b></p>

Dr. Aby Mathew T. MDS  
Principal  
Pushpagiri College of Dental Sciences




No. 25/441/2009– AWD  
Government of India  
Ministry of Fisheries, Animal Husbandry and Dairying  
Department of Animal Husbandry and Dairying  
O/o Committee for the purpose of Control and Supervision of Experiments on Animals  
\*\*\*\*\*

Krishi Bhawan, New Delhi – 110001  
Date: 02/02/2021

To,

Dr Santosh Pillai, Chairman IAEC  
Pushpagiri Medical College Sciences & Research Centre  
Tiruvalla - 689 101 Kerala  
Email: [drsantosh74@gmail.com](mailto:drsantosh74@gmail.com)  
Mobile: 9447596426

Subject: Renewal of Registration and Reconstitution of Institutional Animals Ethics Committee (IAEC) -regarding

Sir,

The registration of Animal House Facility of your establishment with CPCSEA has been renewed **for a period of five years from the date of issue of this letter.**

2. The registration number of Animal House Facility of your establishment is **602/PO/Re/S/02/CPCSEA for Research for Education purpose on small animals.** Henceforth, this registration number may kindly be quoted in all your future correspondence.

3. The CPCSEA has accepted the following members recommended by the establishment.

Name of the IAEC Members	Designation in IAEC
1) Dr Santosh Pillai	Biological Scientist cum Chairperson
2) Dr Bhagyalekshmi N	Scientist In-charge of Animal House Facility cum Member Secretary
3) Dr Prashanth Rathinam	Scientist from different biological discipline
4) Dr Pooja Raghunath	Scientist from different biological discipline
5) Dr P. N Sasidharan	Veterinarian

4. CPCSEA hereby nominates the following members to the Institutional Animals Ethics Committee (IAEC) of your establishment:

Details of Nominee(s)	Nominated as
1) Dr. Sachin J. Shenoy Biomedical Technology Wing, Sree Chitra Tirunal Institute of Medical Science, Poojapura, Thiruvananthapuram 695012, Kerala Contact No :9447432656 Email :sacshen@sctimst.ac.in	Main Nominee
2) Dr. Nishant Kumar Gupta Sr. Research Associate, Arjuna Natural Extracts ltd., PB No 126, Bank Rd, Periyar Nagar, Aluva, Kerala – 683101 Contact No :9400348605 Email :nishant@arjunanatural.com	Link Nominee

Contd..



3) Dr.Prakash K.G Department of Anatomy, Academic Block, Azeezia Institute of Medical Science & Research Meeyannor Post, Kollam, Kerala- 691537 Contact No :9645216564 Email :drprakashkg@gmail.com	Scientist from outside the Institute
4) Dr. Sibi P.I. Dept of Pharmaceutical Sciences, M.G. University, RIMSR, Puthuppally Rubber Board, Kottayam, Kerala – 686009 Contact No :9446883809 Email :sibitho@gmail.com	Socially Aware Nominee

(Please note that any change in IAEC members can be made only with prior approval of CPCSEA.)

5. The IAEC is valid for a period of five years and is coterminous with renewed period of registration. IAEC is required to be reconstituted at the time of renewal of registration as per CPCSEA guidelines.

6. You are requested to convene the meeting of the re-constituted IAEC within a period of 30 days and upload the same on the website of the CPCSEA.

7. It is stated that only above approved IAEC members shall sign, with date, on the attendance sheet of the IAEC meetings, and decisions will be taken only in meetings where quorum is complete. The quorum for holding IAEC meeting is six (6), and Main Nominee, Scientist from outside the Institute and Socially aware Nominee must be present in such meetings. Link Nominee can attend in case main nominee conveys his unavailability in writing to the chairman IAEC. However, the Link Nominee must be invited once a year to update him/ her about the activities of the IAEC. Any decision taken in the meetings of IAEC without quorum shall be considered invalid.

8. It is also to inform you that before commencing any research on large animals you are required to send research protocols with due recommendation of IAEC to CPCSEA for further approval (procedure for submission of Research Protocols is available on the website of CPCSEA).

Yours sincerely,




(Dr. S. K. Dutta)  
Member Secretary (CPCSEA)

Copy for necessary action to: Nominees of CPCSEA.

The Main Nominee is requested to ensure that the IAEC meetings are held regularly as stipulated in the SOP of CPCSEA and submit the Annual Inspection Reports of the Animal House Facility regularly on the Website of CPCSEA.

Dr. Aby Mathew T. MDS  
Principal  
Pushpagiri College of Dental Sciences





PLAGIARISM CHECKER

REGISTER

Sl. No	Date	Name	Designation
1.	1/4/2022	Dr. Supriya G	MDS
2.	5/4/2022	Dr. Joisy P James	"
3.	15/4/22	Dr. Salman Khan	MDS
4.	19/4/22	Dr. Pooja E	"
5.	22/4/22	Dr. Prabha	MDS
6.	22/4/22	Dr. Nisha	"
7.	28/4/22	Dr. Neffin	"
8.	29/4/22	Dr. Shali	"
9.	1/05/22	Dr. Geetha	"
10.	"	Dr. Aiswarya	"
11.	3/5/22	Dr. Saanya	Faculty
12.	12/5/22	Dr. Betey	penb.
13.	16/5/22	Dr. George	Conservative
14.	2/6/2022	Dr. Jisha	pedu. (MDS)
15.	6/6/2022	Dr. Anya Senan	MDS (Endo)
16.	7/6/2022	Dr. Rakhi	" (penb)
17.	8/6/22	Dr. Sani Asha Chaman	Faculty
18.	27/6/2022	Ashik Thomas	Intern.
19.	1/7/2022	Dr. Nidhin	MDS (OMFS)
20.	9/7/2022	Dr. Johnson	MDS (pedu)
21.	14/7/2022	Dr. Saanya John	Faculty
22.	20/7/2022	Dr. Nebu	" (penb)
23.	25/7/2022	Dr. Jhann John	MDS (pedu)
24.	28/8/2022	Dr. Neelhi jsc.	MDS (pedu)
25.	"	Dr. meem	penb. MDS
26.	5/8/22	Fathima	Intern.
27.	13/8/2022	Dr. Betey	MDS
28.	12/8/2022	Fernie J	Intern
29.	13/9/2022	Dr. Pranathi	MDS
30.	14/9/2022	Dr. Rakhi	"
31.	19/9/22	Shan An Roy	Intern
32.	29/9/22	Swathi	Intern



Sl. No	Date	Name	Designation
33	6/6/22	Dr. Rujc	MDS
34	2/6/22	Dr. Nishi	Faculty
35	13/6/22	Dr. Vinod	MDS (gen)
36	18/6/22	Dr. Gopike	"
37	20/6/22	Femine kip	Intern
38	11/7/2022	Dr. Nish	Endo (MDS)
39	12/7/2022	Dr. Anwaje	MDS
40	15/7/2022	Amie parveen	Intern
41	17/7/2022	Dr. hind	MDS
42	19/7/2022	Arora M Alex	Intern
43	21/7/22	Dr. Mani	MDS
44	21/8/2022	Dr. Jini	MDS
45	21/8/2022	Dr. Merin	MDS
46	16/10/2022	Dr. Vimal Thomas	MDS
47	17/10/2022	Susan Ann Roy	Intern
48	22/10/2022	Dr. Sneepriya	MDS
49	23/10/2022	Dr. Vimal Thomas	"
50	26/10/2022	Dr. Salman Khan	MDS
51	27/10/2022	Dr. Saumeje	Faculty
52	30/10/22	Dr. Rinshe Samu	MDS
53	2/11/2023	Dr. Manase	MDS (OMF)
54	3/11/2023	Dr. Keene	"
55	5/11/2023	Jestey	Intern
56	23/11/2023	Dr. Namik	MDS (gen)
57	13/12/2023	Dr. Thomson	"
58	17/12/2023	Joe chacko	Intern
59	24/12/2023	Dr. Jaisy	MDS
60	11/3/2023	Dr. Beley	"
61	17/3/2023	Dr. Ajay	"
62	24/3/2023	Dr. Anje	MDS
63	11/4/2023	Meekeha naswan	Intern
64	19/4/2023	Dr. Gopike	MDS
65			

Sl. No	Date	Name	Designation
66	24/4/2023	Dr. Ashik Thomas	Intern
67	3/5/2023	Dr. Saunnya	Faculty
68	10/5/2023	Angeli Rosa Mathew	Intern
69	20/5/2023	Dr. Heleshmi	para.
70	30/5/2023	D. Mandul	Intern.
71	4/6/2023	Dr. Jincy	MDS
72	4	Dr. Sneepriya	"
73	22/6/2023	Dr. Alebu	Faculty
74	23/6/2023	Silthaxi Sabu	Intern
75	26/6/2023	Anif	MDS
76	6/7/2023	Swellha	Intern.
77	12/7/2023	Dr. Alebu	Intern.
78	19/7/2023	Dr. Johnson	MDS
79	4	Dr. Neelhi	
80	22/7/2023	unnimeya	Intern
81	31/7/2023	Vinilha Maxine	Intern.
82	5/8/2023	Dr. Syan	MDS
83	8/8/2023	Silthaxi Sabu	MDS
84	18/8/2023	Fathima Mohamed	
85	21/8/2023	Dr. Sumil	Faculty.